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CommentaryLowering the annual number of new HIV infections 
is one of 4 national goals [1]. This goal is to be 
achieved by implementing 3 important strategies for 
reducing HIV infections: (1) intensifying HIV pre-
vention efforts in communities where HIV is most 
heavily concentrated, including blacks or African 
Americans (hereafter referred to as blacks); Hispanics 
or Latinos; gay, bisexual, and other men who have sex 
with men (hereafter referred to as MSM); and persons 
who inject drugs (PWID); (2) expanding efforts to 
prevent HIV infection by using a combination of 
effective, evidence-based, scalable approaches 
(including drug treatment and access to sterile needles 
and syringes); and (3) educating the general public 
about the threat of HIV infection and how to prevent 
it. State and local health departments, as well as fed-
eral agencies, are expected to monitor progress 
toward national goals [1].
The Centers for Disease Control and Prevention’s 
(CDC’s) National HIV Behavioral Surveillance 
(NHBS) serves as a key component of its high-impact 
prevention approach to reducing the spread of HIV in 
the United States [2] by providing data for monitoring 
behaviors among populations at risk of acquiring or 
transmitting HIV infection, and identifying the popu-
lations for whom scientifically proven, cost-effective, 
scalable interventions are most appropriate. NHBS 
also helps state and local health departments in areas 
with high AIDS prevalence to monitor selected risk 
behaviors, HIV testing, use of prevention programs, 
and HIV prevalence in 3 populations at high risk of 
HIV infection: MSM, PWID, and heterosexual adults 
at increased risk of HIV [3, 4]. 
This report summarizes findings from the fourth 
NHBS data collection among PWID, which was con-
ducted in 2015; previous years of data among PWID 
(2006, 2009, 2012) have been published [5, 6, 7]. The 
report provides descriptive, unweighted data that can 
be used to describe HIV infection among PWID and 
the percentages of PWID reporting specific risk 
behaviors, HIV testing, and participation in preven-
tion programs. Monitoring these outcomes is useful 
for assessing risk behaviors and the use of prevention 
efforts over time and for identifying new HIV preven-
tion opportunities for this population. HIV Surveillance Special Report 5REPORT CHANGES
CDC routinely assesses NHBS reports to ensure the 
content and methods best meet the information needs 
of the nation. The following reporting changes were 
made from the previous NHBS PWID report [7]:
• Outcomes are no longer reported by HIV-positive 
unaware and HIV-positive aware participants; 
instead, all HIV-positive participants are pre-
sented in a single category.
• Transgender participants are included in tables 
reporting outcomes by gender, where possible; 
sexual behavior data were not available for 
this group. 
• Prescription opioid injection (past 12 months and 
daily) was added (Table 9).
• Daily injection of other drug was removed 
(Table 9).
• Distributive syringe sharing was added 
(Table 10).
• Receipt of syringes from pharmacy was added 
(Tables 11a/b).
• Diagnosis of genital warts or HPV was revised to 
diagnosis of genital warts (HPV diagnosis was 
removed from measure definition) (Table 12).
• Hallucinogen use (past 12 months) was removed 
(Table 14).
• Noninjection prescription opioid use (past 12 
months) was added (Table 16).
Some modifications to measure definitions are 
made routinely to more accurately or more precisely 
describe the outcome or characteristic of interest; 
measure definitions are described in the appendix of 
this report. Additionally, Table 15 is designed as a 
flexible reporting mechanism to respond to emerging 
issues; the outcomes presented in this table vary with 
each report.
TABLE ORGANIZATION
The tables in this report are ordered by content. 
Tables 1 and 5–15 are stratified by HIV status: that is, 
data are presented separately for HIV-negative PWID 
and HIV-positive PWID (HIV status was determined 
from the NHBS HIV test result). A small percentage 
of the sample could not be classified by HIV status No. 18
because they had no valid NHBS HIV test result, 
meaning they did not consent to the HIV test, had an 
indeterminate result, or reported a previous HIV-posi-
tive test result but had a negative NHBS HIV test 
result. For data completeness, data from these partici-
pants are reported in Table 1 in the “No valid NHBS 
HIV test results” column and in Tables 5–15 in the 
“No valid NHBS HIV test results” row.
HIGHLIGHTS
Demographic Characteristics, HIV Prevalence, and 
HIV Testing 
This report describes data from 10,485 PWID who 
participated in NHBS in 2015, of whom 72% were 
male, 28% were female, and <1% were transgender; 
38% were white, 34% were black, and 23% were 
Hispanic or Latino; 37% were aged ≥50 years (Table 
1). Of the participants, 26% had no health insurance, 
19% had not visited a health care provider in the past 
12 months, and the household income of 77% was at 
or below the federal poverty level. 
HIV prevalence is presented in Table 2. In 2015, 
7% of participants with a valid HIV test result tested 
positive for HIV. By gender, HIV prevalence was as 
follows: males (7%), females (7%), and transgender 
(31%). By race and ethnicity, HIV prevalence was as 
follows: blacks (10%), Hispanics or Latinos (8%), 
and whites (4%).
CDC recommends that persons at increased risk of 
HIV infection, including PWID, undergo HIV testing 
at least annually [8]. Among participants who did not 
report a previous HIV-positive test result or who had 
received their first HIV-positive test result less than 
12 months before interview, 57% reported that they 
had been tested for HIV during the 12 months before 
interview, and 91% reported that they had ever been 
tested (Table 3). Similar percentages of males and 
females had been tested recently. 
Among participants who reported a location for 
their most recent HIV test, 68% reported that their 
most recent test was performed in a clinical setting 
(Table 4). The percentage of participants who 
reported that their most recent HIV test was per-
formed in a clinical setting decreased with older age 
and varied by race/ethnicity, with Hispanics and Lati-
nos reporting the lowest percentage of testing within a 
clinical setting (62%).
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Among male and female PWID, condomless vaginal 
sex with a partner of the opposite sex was reported 
least often by HIV-positive PWID (Tables 5 and 7). 
However, male-male anal sex was common among 
HIV-positive men (30%) and almost one-quarter 
(24%) of HIV-positive men reported condomless anal 
sex with men (Table 5). Anal sex with men was less 
common among HIV-negative male PWID (6%). 
These high percentages are particularly concerning in 
light of the increased risk of HIV transmission associ-
ated with condomless anal sex among MSM [9]. 
Condomless sex was common among female 
PWID: 74% reported condomless vaginal sex and 
25% reported condomless anal sex in the past 12 
months (Table 7). As research suggests [10, 11], part-
ner type was an important factor in condom use. 
Among female PWID, condomless sex with a main 
partner (61%) was more common than condomless 
sex with a casual partner (34%; Table 8).
Sexual behaviors are an important mode of HIV 
transmission among male and female PWID. The per-
centages of PWID who engaged in condomless sex 
underscore the importance of using targeted and 
scaled combination HIV prevention strategies that 
include access to and use of condoms, preexposure 
prophylaxis (PrEP), and risk-reduction counseling 
among PWID [12–14].
Injection Drug Use
PWID who engage in frequent or unsafe injections are 
at increased risk of acquiring and transmitting HIV 
and other bloodborne infections, including hepatitis B 
virus infection and hepatitis C virus (HCV) infection 
[15–17]. Approximately 89% of participants reported 
injecting heroin in the past 12 months, and a majority 
(73%) reported injecting heroin daily (Table 9). 
Among HIV-positive PWID, 59% of HIV-positive 
PWID reported daily heroin injection; among HIV-
negative PWID, 74% reported daily heroin injection. 
Injection of methamphetamines in the past 12 
months was reported by 28% of participants (Table 
9). Among HIV-negative participants, report of 
methamphetamine injection decreased with increas-
ing age; the lowest percentage was for black PWID 
(10%; Table 9). 
Injection of prescription opioids has been impli-
cated in a recent outbreak of HIV infection in a rural 
community in Indiana [18]. Twenty percent of PWID No. 18
reported injecting prescription painkillers in the past 
12 months. Among HIV-negative PWID, reported use 
was highest (32%) among those 18–24 years of age 
and decreased with increasing age. 
One-time use of sterile needles and syringes 
remains the safest, most effective way to limit HIV 
transmission due to drug injection [19]. Approxi-
mately 1 in 3 PWID reported using a syringe that had 
been used by someone else; receptive syringe sharing 
was reported by 25% of HIV-positive PWID, and 34% 
of HIV-negative PWID (Table 10). Among HIV-
negative PWID, the percentage reporting receptive 
syringe sharing was lowest among black PWID (21%), 
and highest among young PWID and decreased with 
increasing age. Additionally, 41% of PWID reported 
distributive syringe sharing; twice as many HIV-
negative PWID reported distributive syringe sharing 
(43%) than HIV-positive PWID (21%). 
Receiving sterile syringes from syringe services 
programs (SSPs) reduces barriers to safe injection 
practices among PWID and increases access to other 
prevention services, including substance use disor-
der treatments [20]. Over half (52%) of participants 
reported receiving syringes from SSPs during the 
past 12 months (Table 11a); however, the percent-
age of HIV-negative PWID who received syringes 
from SSPs varied greatly by city, from 2% to 90% 
(Table 11b).
Sexually Transmitted Infections and Hepatitis C 
Virus Infections
Sexually transmitted infections (STIs) can increase 
the likelihood of acquiring and transmitting HIV [21]. 
The percentages of PWID who reported a diagnosis of 
any bacterial STI (chlamydia, gonorrhea, or syphilis) 
during the past 12 months were highest among those 
who were HIV-positive (11%) and lowest among 
those who were HIV-negative (4%; Table 12). 
HCV testing is recommended at least once for 
anyone who has ever injected drugs; HCV testing is 
recommended at least annually for persons who cur-
rently inject drugs and who are thus at continued 
risk of infection [22]. NHBS reports data on lifetime 
testing for HCV: the percentage among all PWID 
was high (81%; Table 13). Furthermore, substantial 
percentages of participants reported a diagnosis of 
hepatitis C (54% of HIV-positive PWID, 44% of 
HIV-negative PWID). Diagnoses of STIs and HCV 
infection may be more common among HIV-HIV Surveillance Special Report 7positive PWID because of increased screening for 
this group. Moreover, HIV-positive PWID may be 
more likely to be coinfected with HCV [23].
Substance Use
Table 14 presents data on noninjection drug use. 
HIV-negative PWID reported more use of nonin-
jection drugs (76%) than HIV-positive PWID 
(67%). Marijuana use was the most common nonin-
jection drug used by PWID in the past 12 months. 
Over half (52%) of HIV-negative PWID reported 
marijuana use. 
Additional Outcomes
Table 15 presents data on additional outcomes 
related to the risk of HIV transmission and acquisi-
tion among PWID.
Although exposure to HIV through injection prac-
tices is a primary concern, sexual risk factors also 
play an important role in transmission to and from 
PWID. Condomless sex with an HIV-discordant 
partner and exchange sex were common. More than a 
fourth (26%) of PWID reported exchange sex with a 
casual partner in the past 12 months. Exchange sex 
with a casual partner in the past 12 months was most 
often reported by HIV-positive PWID (33%). Con-
domless sex with an HIV-discordant partner at last 
sex was most often reported by HIV-negative PWID 
(31%). However, more than one in four HIV-positive 
PWID (27%) also reported this behavior.
In 2014, after the publication of scientific evidence 
that anti-HIV medication taken by HIV-negative per-
sons can prevent HIV infection, CDC released clini-
cal guidance recommending the use of PrEP for 
persons at increased risk of contracting HIV [12]. In 
2015, less than 10% of the sample had heard of PrEP, 
and a small percentage of HIV-negative PWID 
(0.3%) reported taking PrEP as indicated to prevent 
HIV infection.
Treatment for drug abuse is an important method of 
HIV risk reduction because it provides access to HIV 
testing and treatment and can help to reduce transmis-
sion. Of the participants, 44% received drug abuse 
treatment during the past 12 months.
Access to safe syringe disposal (such as through 
SSPs) can decrease the number of used syringes in the 
community and reduce accidental needle sticks. Only 
18% of PWID reported exclusively disposing of their 
used syringes safely. No. 18
For many PWID, injection drug use can be a life-
long struggle. Among participants, the median num-
bers of years between the NHBS interview and their 
first injection was 18 years. The median number of 
years since first injection increased with increasing 
age. Among participants aged 50 years or older, the 
median time since first injection was 36 years. 
Receipt of HIV Care
One national HIV prevention goal is to increase the 
proportion of persons with recently diagnosed HIV 
infection who are linked to clinical care [1]. Among 
self-reported HIV-positive PWID, 92% reported hav-
ing ever visited a health care provider for HIV care, 
58% reported that they did so within 3 months after 
diagnosis, and 83% reported visiting a health care 
provider for HIV care in the 6 months before inter-
view. Current use of antiretroviral therapy was 
reported by 71% of self-reported HIV-positive PWID: 
76% of blacks, 66% of whites, and 67% of Hispanics 
or Latinos (Table 16).
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Technical NotesNHBS conducts rotating cycles of behavioral surveys 
among MSM, PWID, and heterosexual adults at 
increased risk of HIV [4]; data are collected in annual 
cycles from 1 risk group per year so that each popula-
tion is surveyed once every 3 years. The same general 
eligibility criteria are used in each cycle: age of ≥18 
years, current residence in a participating city, no pre-
vious participation in NHBS during the current survey 
cycle, ability to complete the survey in either English 
or Spanish, and ability to provide informed consent. In 
addition to these basic NHBS eligibility requirements, 
participation in the 2015 IDU NHBS cycle was limited 
to persons who (1) reported injecting a drug that was 
not prescribed for them during the past 12 months; and 
(2) presented physical evidence of recent injection 
(e.g., track marks) or adequately described their injec-
tion practices.
A standardized questionnaire is used to collect 
information about behavioral risks for HIV infection, 
HIV testing, and use of HIV prevention services. The 
anonymous in-person survey is administered by a 
trained interviewer using a portable computer. The 
goal of each participating city is to interview 500 eli-
gible persons. All participants are offered an anony-
mous HIV test, which is linked to the survey data 
through a unique survey identifier. 
Activities for NHBS were approved by CDC [24, 
25] and by local institutional review boards (IRBs) for 
each of the 20 participating cities. 
PARTICIPATING CITIES
State and local health departments eligible to partici-
pate in NHBS are among those whose jurisdictions 
include a metropolitan statistical area (MSA) or a 
specified division with high AIDS burden. In 2015, 
NHBS was conducted in 20 MSAs (see list at the end 
of the report), which represented approximately 45% 
of all persons living with HIV infection in urban areas 
with a population of at least 500,000 in 2014 [26]. 
Throughout this report, MSAs and divisions are 
referred to by the name of the principal city. 
SAMPLING METHOD
The stigma associated with injection drug use pres-
ents particular challenges to sampling strategies for 
HIV Surveillance Special Report 9surveillance and research efforts among PWID. Par-
ticipants in the 2015 NHBS cycle were recruited by 
using respondent-driven sampling (RDS) [27, 28]. 
Recruitment started with a limited number of initial 
participants who were chosen by referrals from peo-
ple who knew the local population of PWID or 
through outreach to areas where PWID could be 
found. Initial participants who completed the eligibil-
ity screener and were found eligible were adminis-
tered the survey, and those who completed the survey 
were asked to recruit up to 5 persons whom they knew 
personally and who injected drugs. Those persons, in 
turn, completed the survey and were asked to recruit 
others by using a system of coded coupons. This 
recruitment process continued until the sample size 
was reached or the sampling period ended. Partici-
pants received incentives for participating in the sur-
vey and for recruiting others.
DATA COLLECTION
Persons who brought a valid coupon to an NHBS field 
site were escorted to a private area for eligibility 
screening. For those who met eligibility requirements, 
trained interviewers obtained informed consent and 
conducted face-to-face interviews, which took 
approximately 40 minutes and consisted of questions 
concerning participants’ demographic characteristics, 
HIV testing history, sexual and drug-use behaviors, 
HCV testing and diagnosis of hepatitis C, STI testing 
and diagnosis, and use of HIV prevention services and 
programs. In exchange for the time spent taking part 
in the interview, participants received $20–$30 
(amount determined locally). 
HIV testing was performed for participants who 
consented; blood-based rapid testing was performed 
in the field for all consenting participants, and blood 
or oral confirmatory specimens were collected for 
supplemental laboratory-based testing. A nonreactive 
rapid test result was considered HIV-negative; a reac-
tive rapid test result was considered HIV-positive if 
confirmed by supplemental laboratory testing. Partic-
ipants also received $10–$25 for HIV testing. 
Participants who agreed to recruit others received an 
additional incentive of $10 for each recruit (up to 5) 
who completed the interview. No. 18
DATA ANALYSIS
This surveillance report presents descriptive data; no 
statistical tests were performed. In addition, these 
data are cross-sectional; we did not attempt to infer 
causal relationships. Reported numbers less than 12 
and percentages based on these numbers, should be 
interpreted with caution because the numbers are 
considered unreliable.
Data for this report are not weighted. The purpose 
of this report is to provide a detailed summary of sur-
veillance data collected as part of the NHBS 2015 
cycle; unweighted data provide an efficient and trans-
parent way to do so. Further, unweighted analysis 
allows for detailed reporting of outcomes among 
small subgroups of the PWID population. Weighted 
analysis of HIV prevalence and selected HIV-
associated outcomes is presented elsewhere [29].
In total, 13,633 persons were recruited to partici-
pate in NHBS in 2015. Of those, 2,955 did not meet 
NHBS eligibility criteria and were excluded from this 
report. An additional 193 eligible persons were 
excluded from this report because of lost data during 
electronic uploads, lack of consent to the survey, 
incomplete survey data, or survey responses of ques-
tionable validity. 
The full analysis sample for this report includes 
2015 NHBS cycle participants who consented to and 
completed the survey (n = 10,485, Table 1). Addi-
tional inclusion criteria were applied for certain anal-
yses of HIV infection and of HIV-associated 
behaviors; details of each analysis sample can be 
found in the footnotes of each table. 
SUPPLEMENTAL MATERIAL
Infographic: HIV infection, risk, and prevention 
among persons who inject drugs (PWID)—National 
HIV Behavioral Surveillance (NHBS), 20 U.S. cities, 
2015 (PDF file is attached; also available at http://
www.cdc.gov/hiv/pdf/library/reports/surveillance/
cdc-hiv-hssr-nhbs-pwid-infographic.pdf).
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Appendix: Measurement NotesSOCIODEMOGRAPHIC CHARACTERISTICS
• Gender: Male, female, or transgender. 
• Age: Calculated from the reported date of birth; 
age categories were chosen for epidemiologic 
relevance and consistency of reporting across all 
3 National HIV Behavioral Surveillance 
(NHBS) populations. 
• Race/ethnicity: Participants reported 1 or more 
race categories (American Indian or Alaska 
Native, Asian, Black or African American, Native 
Hawaiian or Other Pacific Islander, and White). 
Hispanic or Latino ethnicity was asked separately; 
participants reporting Hispanic or Latino ethnicity 
were considered Hispanic or Latino, regardless of 
reported race. Participants reporting multiple 
races (but not Hispanic or Latino ethnicity) were 
classified as multiple races. 
• Education: Highest level of education completed. 
• Household income: Participants were asked 
about their combined monthly or yearly house-
hold income (in US$) from all sources during the 
12 months before interview. The number of per-
sons in poverty was determined by using the U.S. 
Department of Health and Human Services pov-
erty guidelines for 2015. These guidelines are 
issued yearly for the United States and are one 
indicator used for determining eligibility for 
many federal and state programs. The 2015 
guidelines [1] were used for participants inter-
viewed in 2015. Because the poverty guidelines 
are not defined for the territory of Puerto Rico, 
the guidelines for the contiguous states and 
Washington, DC, were used for this jurisdiction. 
Participants were asked to specify the range of 
their income by selecting from a list of income 
ranges. If the participant’s income range and 
household size resulted in an ambiguous determi-
nation of poverty level, the participant’s house-
hold income was assumed to be the low point of 
the income range.
• Health insurance: Currently having some form of 
health insurance. 
HIV Surveillance Special Report 1• Homeless: Living on the street, in a shelter, in a 
single-room–occupancy hotel, or in a car at any 
time in the past 12 months. 
• Incarcerated: Having been held in a detention 
center, jail, or prison, for more than 24 hours in 
the past 12 months. 
• City: Throughout this report, eligible metropoli-
tan statistical areas (MSAs) and divisions are 
referred to by the name of the principal city. State 
and local health departments eligible to partici-
pate in NHBS are among those whose jurisdic-
tions included an MSA or a specified division 
within an MSA with high prevalence of HIV. In 
2015, NHBS was conducted in 20 MSAs (see list 
at the end of the report), which represented 
approximately 45% of all HIV diagnoses in urban 
areas with a population of at least 500,000. 
HIV STATUS 
HIV testing was performed for participants who con-
sented to testing; blood or oral specimens were col-
lected for either rapid testing in the field or 
laboratory-based testing. 
• HIV-negative: Nonreactive NHBS HIV test 
result, or a negative laboratory test result if rapid 
test was not conducted and no self-report of a pre-
vious HIV-positive test result. 
• HIV-positive: Reactive rapid NHBS HIV test 
result confirmed by supplemental laboratory-
based testing, or a positive result by laboratory-
based testing without a rapid HIV test.
• No valid NHBS HIV test result: Includes partici-
pants who did not consent to NHBS HIV testing, 
had an indeterminate result, or reported a previ-
ous HIV-positive test result but had an HIV-
negative NHBS HIV test result. For data 
completeness, participants who did not have a 
valid test result were included in this report but 
listed separately in all tables that report outcomes 
by HIV status.
HIV TESTING 
• Ever tested: Having had an HIV test during one’s 
lifetime. 3 No. 18
• Tested in past 12 months: Having had an HIV test 
during the 12 months before interview. 
• Clinical setting: Participants reported the loca-
tion of their most recent HIV test: private doc-
tor’s office (including health maintenance 
organizations), emergency room, hospital (inpa-
tient), public health clinic or community health 
center, family planning or obstetrics clinic, cor-
rectional facility (jail or prison), or drug treat-
ment program. 
• Nonclinical setting: Participants reported the 
location of their most recent HIV test: HIV coun-
seling and testing site, HIV street outreach pro-
gram or mobile unit, syringe services program 
(SSP), or home. 
• Other locations: “Other” locations could not be 
classified and are excluded from the clinical/non-
clinical setting classification.
SEXUAL BEHAVIORS
• Any sex: Includes vaginal, oral, or anal sex. 
• Vaginal sex: Penis inserted into a partner’s 
vagina.
• Oral sex: Mouth on a partner’s vagina or penis.
• Anal sex: Penis inserted into a partner’s anus.
• Condomless sex: Vaginal or anal sex during 
which a condom is not used. 
• Main partner: Person with whom the participant 
has sex and to whom he or she feels most commit-
ted (e.g., girlfriend/boyfriend, wife/husband, sig-
nificant other, or life partner). 
• Casual partner: Person with whom the partici-
pant has sex, but to whom he or she does not feel 
committed or whom he or she does not know 
very well. 
INJECTION DRUG USE AND BEHAVIORS
• Injected in the past 12 months: A drug (excluding 
those prescribed for him or her) the participant 
reported injecting at least 1 time during the 12 
months before interview. 
• Injected daily: A drug (excluding those pre-
scribed for him or her) the participant reported 
injecting daily during the 12 months before 
interview. 
• Heroin: Injected by itself.HIV Surveillance Special Report 1• Speedball: Heroin and cocaine injected together 
through a single injection.
• Powder or crack cocaine: Injection of crack or 
powdered cocaine. 
• Methamphetamine: Injection of methamphet-
amine. 
• Prescription opioids: Injection of painkillers, 
such as Oxycontin, Dilaudid, morphine, Perco-
cet, or Demerol.
• Other drug: Injection of any drug other than those 
listed above. 
• Receptive sharing of syringes: Injecting with a 
syringe or needle that had already been used by 
someone else.
• Receptive sharing of injection equipment: Using 
a cooker or cotton (used to filter particles from 
drug solution) that had already been used by 
someone else or using shared water for rinsing or 
injection. 
• Receptive sharing of syringes to divide drugs: 
Dividing a drug solution by using a syringe that 
had already been used by someone else for 
injection.
• Any receptive sharing: Any combination of the 3 
receptive sharing measures listed above.
• Distributive sharing: A participant giving their 
needle to someone else to use after he or she had 
already used it for injection.
RECEIPT OF PREVENTION MATERIALS
• Syringes from SSPs: Received any syringes from 
SSPs during the 12 months before interview. 
• Syringes from pharmacy: Received any 
syringes from a pharmacy during the 12 months 
before interview. 
• Injection equipment from SSPs: Received injec-
tion equipment from SSPs during the 12 months 
before interview. Injection equipment includes 
items such as cookers, cotton, or water for rinsing 
needles; does NOT include syringes or needles.
• Free condoms: Received free condoms during the 
12 months before interview, excluding those 
given by a friend, relative, or sex partner. 
• Individual- or group-level intervention: Defined 
as either one-on-one conversations with an out-
reach worker, a counselor, or a prevention pro-4 No. 18
gram worker about ways to prevent HIV, or 
participating in any organized sessions that 
involve a small group of people discussing ways 
to prevent HIV infections, excluding informal 
discussions with friends. Conversations that were 
part of obtaining an HIV test were excluded.
SEXUALLY TRANSMITTED INFECTIONS
• Chlamydia: Received a diagnosis of chlamydia 
during the 12 months before interview. 
• Gonorrhea: Received a diagnosis of gonorrhea 
during the 12 months before interview. 
• Syphilis: Received a diagnosis of syphilis during 
the 12 months before interview. 
• Any bacterial STI: Received a diagnosis of chla-
mydia, gonorrhea, or syphilis during the 12 
months before interview. 
• Genital warts: Received a diagnosis of genital 
warts during one’s lifetime. 
• Genital herpes: Received a diagnosis of genital 
herpes during one’s lifetime.
NONINJECTION SUBSTANCE USE
Participants were asked about their use of noninjec-
tion drugs (excluding those prescribed for them) 
during the 12 months before interview and their use of 
alcohol during the 30 days before interview. Partici-
pants were not limited in the number of substances 
they could report using. Participants were considered 
to have used a substance if they reported using that 
substance with any frequency other than “never.” 
• Binge drinking: Consumed 5 or more drinks in 
about 2 hours (males) or 4 or more drinks in 
about 2 hours (females) during the 30 days 
before interview.
• Marijuana: Used marijuana during the 12 months 
before interview.
• Cocaine: Used powdered cocaine that is smoked 
or snorted during the 12 months before interview.
• Ecstasy: Used X or ecstasy during the 12 months 
before interview.
• Prescription opioids: Used pain killers, such as 
Oxycontin, Vicodin, morphine, or Percocet, by 
means other than injection during the 12 months 
before interview.
HIV Surveillance Special Report 1• Downers: Used benzodiazepines, such as Klono-
pin, Valium, Ativan, or Xanax, by means other 
than injection during the 12 months before inter-
view.
• Methamphetamine: Used methamphetamines, 
including meth, crystal meth, speed, or crank, by 
means other than injection during the 12 months 
before interview.
• Crack: Used crack cocaine during the 12 months 
before interview.
• Heroin: Used heroin that is smoked or snorted 
during the 12 months before interview.
• Any noninjection drug: Used any noninjection 
drug, excluding alcohol, during the 12 months 
before interview. 
HEPATITIS C VIRUS INFECTION
• Hepatitis C testing: Having had a hepatitis C test 
during one’s lifetime. 
• Hepatitis C diagnosis: Having ever been told that 
they had hepatitis C infection by a doctor, nurse, 
or other health care provider.
ADDITIONAL OUTCOMES
The additional outcomes table includes outcomes that 
were of particular interest at the time of publication, 
but were not included in the other tables.
• Number of sex partners: Median number of het-
erosexual sex partners during the 12 months 
before interview; first and third quartiles (25th 
and 75th percentiles) are also reported. 
• Exchange sex among casual partners: For 
females, “exchange sex” refers to receiving 
money or drugs from a casual male partner in 
exchange for sex. For males, “exchange sex” 
refers to giving money or drugs to a casual female 
partner in exchange for sex, or giving or receiving 
money or drugs from a casual male partner in 
exchange for sex. 
• Condomless sex with an HIV-discordant partner 
at last sex: A composite measure based on self-
reported HIV status of the participant (positive, 
negative, or unknown), the participant’s knowl-
edge of the HIV status of his or her most recent 
sexual partner (positive, negative, or unknown), 
and whether the participant reported engaging in 
vaginal or anal sex without a condom during his 5 No. 18
or her last sexual encounter with the partner. A 
partner was considered to be of discordant or 
unknown HIV status if the participant reported he 
or she did not know the HIV status of at least one 
member of the partnership (the participant or the 
partner) or if one member of the partnership was 
known to be HIV-positive while the other was 
known to be HIV-negative. The result of the 
NHBS HIV test completed after the interview 
was not factored into this measure. 
• Heard of PrEP: Ever having heard of people who 
do not have HIV taking PrEP, the antiretroviral 
medicine taken every day for months or years to 
reduce the risk of getting HIV.
• Took PrEP: At any point during the 12 months 
before interview, taking PrEP every day for at 
least 2 months to reduce the risk of getting HIV 
(not including time when taking antiretroviral 
medicine for only a few days at a time).
• Drug treatment: Participating in a program to 
treat drug use (including outpatient, inpatient, 
residential, detox, methadone treatment, or 12-
step programs) during the 12 months before 
interview. 
• Safe syringe disposal only: Syringes were dis-
posed of by putting them in a medical waste 
container and/or by exchanging them at an SSP, 
and no unknown or unsafe disposal method was 
indicated.
• Years since first injection: Number of years since 
the participant first injected drugs not prescribed 
to him or her, based on the participant’s reported 
age at first injection. 
RECEIPT OF HIV CARE
Participants who reported having received a positive 
HIV test result before interview were asked about 
their receipt of HIV care. Specifically, participants 
were asked: the date of their first HIV-positive test 
result; if they had ever visited a doctor, nurse, or 
other health care provider for a medical evaluation or 
care related to their HIV infection; the date of their 
first visit to a health care provider for HIV care after 
learning they had HIV; the date of their most recent 
visit to a health care provider for HIV care; and 
whether they were currently taking any anti-HIV 
antiretroviral medicines. 
HIV Surveillance Special Report 1• Visited health care provider about HIV, ever: 
Having ever visited a health care provider for 
HIV care. 
• Visited health care provider about HIV, within 3 
months after diagnosis: Having visited a health 
care provider for HIV care within 3 months after 
the date of his or her first HIV-positive test result. 
• Visited health care provider about HIV, in the 
past 6 months: Having visited a health care pro-
vider for HIV care during the 6 months before 
date of interview.
• Currently taking anti-HIV medications: Taking 
anti-HIV antiretroviral medicines at the time of 
interview.
REFERENCE
1. Department of Health and Human Services. Annual 
update of the HHS Poverty Guidelines. Federal Register. 
2015;80(14):3236–3237. 6 No. 18
H



































Table 1. Selected characteristics of persons who inject drugs—National HIV Behavioral Surveillance, 20 U.S. ci
HIV-negativea HIV-positiveb
No valid NHBS HIV 
test resultc
No. % No. % No. % N
Gender
Male 6,954 71.9 506 69.8 61 71.8 7
Female 2,685 27.8 203 28.0 22 25.9 2
Transgender 36 0.4 16 2.2 2 2.4
Age at interview (yr)
18–24 578 6.0 8 1.1 0 0.0
25–29 1,148 11.9 33 4.6 7 8.2 1
30–39 2,317 23.9 114 15.7 19 22.4 2
40–49 2,159 22.3 246 33.9 18 21.2 2
50 3,473 35.9 324 44.7 41 48.2 3
Race/ethnicity
American Indian/Alaska Native 99 1.0 6 0.8 1 1.2
Asian 28 0.3 1 0.1 0 0.0
Black/African American 3,137 32.4 349 48.1 46 54.1 3
Hispanic/Latinod 2,162 22.3 178 24.6 17 20.0 2
Native Hawaiian/Other Pacific Islander 15 0.2 1 0.1 0 0.0
White 3,837 39.7 158 21.8 16 18.8 4
Multiple races 380 3.9 28 3.9 4 4.7
Education
Less than high school 2,879 29.8 278 38.3 21 24.7 3
High school diploma or equivalent 3,991 41.3 254 35.0 41 48.2 4
Some college or technical degree 2,418 25.0 164 22.6 18 21.2 2
College degree or more 386 4.0 29 4.0 5 5.9
Household incomee
At or below the federal poverty level 7,428 76.8 590 81.4 72 84.7 8
Above the federal poverty level 2,172 22.4 131 18.1 11 12.9 2
Health insurance
Yes 7,036 72.7 606 83.6 68 80.0 7
No 2,601 26.9 118 16.3 17 20.0 2
Visited a health care provider, past 12 months
Yes 7,756 80.2 642 88.6 79 92.9 8
No 1,916 19.8 83 11.4 6 7.1 2
Homeless,f past 12 months
Yes 6,237 64.5 409 56.4 55 64.7 6
No 3,438 35.5 316 43.6 30 35.3 3
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Abbreviations: NHBS, National HIV Behavioral Surveillance; PWID, persons who inject drugs [footnotes only].
Note. “Past 12 months” refers to the 12 months preceding interview.
a PWID with a valid negative NHBS HIV test result.
b PWID with a reactive rapid NHBS HIV test result confirmed by supplemental laboratory-based testing, or a positive result by laboratory-based testin
test. 
c PWID who did not have a valid NHBS HIV test result (i.e., a participant who did not consent to the HIV test, had an indeterminate result, or reported a
test result but had an HIV-negative NHBS HIV test result).
d Hispanics/Latinos can be of any race. 
e Poverty level is based on household income and household size.
f Living on the street, in a shelter, in a single-room–occupancy hotel, or in a car. 
g Having been held in a detention center, jail, or prison for more than 24 hours.
Incarcerated,g past 12 months
Yes 3,617 37.4 179 24.7 33 38.8 3
No 6,052 62.6 545 75.2 52 61.2 6
City
Atlanta, GA 388 4.0 36 5.0 6 7.1
Baltimore, MD 501 5.2 74 10.2 11 12.9
Boston, MA 489 5.1 11 1.5 10 11.8
Chicago, IL 528 5.5 9 1.2 4 4.7
Dallas, TX 493 5.1 12 1.7 4 4.7
Denver, CO 569 5.9 24 3.3 4 4.7
Detroit, MI 566 5.9 15 2.1 2 2.4
Houston, TX 473 4.9 44 6.1 5 5.9
Los Angeles, CA 510 5.3 16 2.2 5 5.9
Miami, FL 444 4.6 76 10.5 0 0.0
Nassau-Suffolk, NY 201 2.1 8 1.1 2 2.4
New Orleans, LA 577 6.0 31 4.3 6 7.1
New York City, NY 473 4.9 50 6.9 3 3.5
Newark, NJ 340 3.5 43 5.9 3 3.5
Philadelphia, PA 626 6.5 32 4.4 0 0.0
San Diego, CA 602 6.2 20 2.8 1 1.2
San Francisco, CA 454 4.7 77 10.6 7 8.2
San Juan, PR 480 5.0 61 8.4 5 5.9
Seattle, WA 505 5.2 25 3.4 3 3.5
Washington, DC 456 4.7 61 8.4 4 4.7
Total 9,675 100.0 725 100.0 85 100.0 10
Table 1. Selected characteristics of persons who inject drugs—National HIV Behavioral Surveillance, 20 U.S. ci
HIV-negativea HIV-positiveb
No valid NHBS HIV 
test resultc
No. % No. % No. % N
H









































Abbreviations: PWID, persons who inject drugs [footnotes only]; NHBS, National HIV Behavioral Surveillance [footnotes only].
Data include PWID with a valid NHBS HIV test result.
a PWID with a reactive rapid NHBS HIV test result confirmed by supplemental laboratory-based testing, or a positive result by laboratory-based testing without a rapid HIV test. 
b Hispanics/Latinos can be of any race. 
Table 2. HIV prevalence among persons who inject drugs, by gender—National HIV Behavioral Surveillance, 20 U.S. cities, 2015 
Male Females Transgender
HIV-positivea Total HIV-positivea Total HIV-positivea Total HIV
No. % No. No. % No. No. % No. No.
Age at interview (yr)
18–24 7 1.9 373 1 0.5 209 0 0.0 4 8
25–29 23 2.7 839 9 2.7 338 1 25.0 4 33
30–39 84 4.9 1,717 24 3.4 700 6 42.9 14 114
40–49 157 9.3 1,689 84 12.0 701 5 33.3 15 246
≥50 235 8.3 2,842 85 9.0 940 4 26.7 15 324
Race/ethnicity
American Indian/Alaska Native 4 6.3 63 2 5.0 40 0 0.0 2 6
Asian 1 4.3 23 0 0.0 5 0 0.0 1 1
Black/African American 221 8.8 2,500 116 12.1 957 12 41.4 29 349
Hispanic/Latinob 138 7.7 1,797 38 7.1 536 2 28.6 7 178
Native Hawaiian/Other Pacific Islander 1 11.1 9 0 0.0 7 0 . 0 1
White 117 4.2 2,788 40 3.3 1,197 1 10.0 10 158
Multiple races 21 7.9 265 6 4.3 140 1 33.3 3 28
City
Atlanta, GA 25 8.0 313 11 10.0 110 0 0.0 1 36
Baltimore, MD 51 12.4 410 21 12.9 163 2 100.0 2 74
Boston, MA 10 2.6 380 0 0.0 118 1 50.0 2 11
Chicago, IL 7 1.8 393 2 1.4 144 0 . 0 9
Dallas, TX 8 2.3 352 4 2.6 153 0 . 0 12
Denver, CO 20 4.8 419 4 2.3 172 0 0.0 2 24
Detroit, MI 7 1.8 379 8 4.0 200 0 0.0 2 15
Houston, TX 36 8.4 427 5 6.1 82 3 37.5 8 44
Los Angeles, CA 13 3.5 376 3 2.0 149 0 0.0 1 16
Miami, FL 46 11.5 399 30 25.0 120 0 0.0 1 76
Nassau-Suffolk, NY 4 2.9 136 4 5.5 73 0 . 0 8
New Orleans, LA 28 6.1 460 1 0.7 145 2 66.7 3 31
New York City, NY 26 7.1 368 20 13.7 146 4 44.4 9 50
Newark, NJ 23 10.1 228 20 13.1 153 0 0.0 2 43
Philadelphia, PA 25 5.1 489 7 4.3 164 0 0.0 5 32
San Diego, CA 17 4.0 421 1 0.5 196 2 40.0 5 20
San Francisco, CA 60 15.6 384 15 10.6 142 2 40.0 5 77
San Juan, PR 52 11.2 464 9 11.8 76 0 0.0 1 61
Seattle, WA 19 5.6 339 6 3.2 190 0 0.0 1 25
Washington, DC 29 9.0 323 32 16.7 192 0 0.0 2 61
Total 506 6.8 7,460 203 7.0 2,888 16 30.8 52 725
Abbreviation: PWID, persons who inject drugs [footnotes only].
Note. CDC recommends that all persons who inject drugs be tested for HIV at least annually. 
Data include all PWID who did not report a previous HIV-positive test result and PWID who received their first HIV-positive test result less than 12 
months before the interview. 
a “Past 12 months” refers to the 12 months preceding interview.
b Hispanics/Latinos can be of any race.
Table 3. HIV testing among persons who inject drugs—National HIV Behavioral Surveillance, 20 U.S. cities, 2015 
Ever tested
Tested during past 
12 monthsa
No. % No. % Total No.
Gender
Male 6,489 90.6 4,049 56.5 7,163
Female 2,591 93.4 1,618 58.3 2,774
Transgender 38 92.7 31 75.6 41
Age at interview (yr)
18–24 445 76.5 318 54.6 582
25–29 1,000 85.8 686 58.8 1,166
30–39 2,193 92.5 1,408 59.4 2,372
40–49 2,127 94.0 1,284 56.7 2,263
≥50 3,353 93.3 2,002 55.7 3,595
Race/ethnicity
American Indian/Alaska Native 90 90.0 55 55.0 100
Asian 26 92.9 16 57.1 28
Black/African American 3,123 94.9 2,035 61.9 3,290
Hispanic/Latinob 2,024 90.3 1,245 55.6 2,241
Native Hawaiian/Other Pacific Islander 12 80.0 6 40.0 15
White 3,463 88.8 2,114 54.2 3,898
Multiple races 362 93.8 216 56.0 386
City
Atlanta, GA 364 91.0 240 60.0 400
Baltimore, MD 526 98.5 371 69.5 534
Boston, MA 470 94.4 296 59.4 498
Chicago, IL 490 91.8 321 60.1 534
Dallas, TX 452 89.7 247 49.0 504
Denver, CO 506 88.2 296 51.6 574
Detroit, MI 504 87.5 222 38.5 576
Houston, TX 455 93.2 275 56.4 488
Los Angeles, CA 482 92.2 302 57.7 523
Miami, FL 412 88.6 300 64.5 465
Nassau-Suffolk, NY 186 90.3 115 55.8 206
New Orleans, LA 531 89.1 337 56.5 596
New York City, NY 472 96.7 372 76.2 488
Newark, NJ 333 94.1 194 54.8 354
Philadelphia, PA 590 92.0 407 63.5 641
San Diego, CA 509 83.6 265 43.5 609
San Francisco, CA 457 95.2 298 62.1 480
San Juan, PR 462 89.5 219 42.4 516
Seattle, WA 449 87.9 236 46.2 511
Washington, DC 468 97.3 385 80.0 481
Total 9,118 91.4 5,698 57.1 9,978
HIV Surveillance Special Report 20 No. 18
Abbreviations: PWID, persons who inject drugs [footnotes only]; HMO, health maintenance organization [footnotes only].
Note. Data report setting of most recent HIV test. Data exclude PWID who did not report an HIV test during the past 12 months or who 
reported receiving an HIV-positive test result more than 12 months before interview. Data exclude “Other” locations, which could not be 
classified as clinical/nonclinical settings.
a Clinical settings include private doctor’s office (including HMO), emergency department, hospital (inpatient), public health clinic or community health 
center, family planning or obstetrics clinic, correctional facility, or drug treatment program.
b Nonclinical settings include HIV counseling and testing site, HIV street outreach program or mobile unit, syringe services program, or home.
c Hispanics/Latinos can be of any race.
Table 4. Setting of most recent HIV test among persons who inject drugs and who were tested for HIV during the 
12 months preceding interview—National HIV Behavioral Surveillance, 20 U.S. cities, 2015 
Clinical settinga Nonclinical settingb
No. % No. % Total No.
Gender
Male 2,721 67.2 1,123 27.7 4,049
Female 1,126 69.6 420 26.0 1,618
Transgender 19 61.3 9 29.0 31
Age at interview (yr)
18–24 253 79.6 48 15.1 318
25–29 494 72.0 146 21.3 686
30–39 983 69.8 368 26.1 1,408
40–49 847 66.0 372 29.0 1,284
≥50 1,289 64.4 618 30.9 2,002
Race/ethnicity
American Indian/Alaska Native 41 74.5 7 12.7 55
Asian 11 68.8 4 25.0 16
Black/African American 1,327 65.2 606 29.8 2,035
Hispanic/Latinoc 777 62.4 411 33.0 1,245
Native Hawaiian/Other Pacific Islander 4 66.7 1 16.7 6
White 1,540 72.8 476 22.5 2,114
Multiple races 157 72.7 46 21.3 216
City
Atlanta, GA 170 70.8 55 22.9 240
Baltimore, MD 226 60.9 122 32.9 371
Boston, MA 224 75.7 66 22.3 296
Chicago, IL 238 74.1 74 23.1 321
Dallas, TX 196 79.4 39 15.8 247
Denver, CO 207 69.9 73 24.7 296
Detroit, MI 183 82.4 36 16.2 222
Houston, TX 216 78.5 46 16.7 275
Los Angeles, CA 163 54.0 125 41.4 302
Miami, FL 205 68.3 73 24.3 300
Nassau-Suffolk, NY 96 83.5 17 14.8 115
New Orleans, LA 266 78.9 47 13.9 337
New York City, NY 231 62.1 121 32.5 372
Newark, NJ 109 56.2 76 39.2 194
Philadelphia, PA 229 56.3 174 42.8 407
San Diego, CA 202 76.2 45 17.0 265
San Francisco, CA 220 73.8 53 17.8 298
San Juan, PR 93 42.5 111 50.7 219
Seattle, WA 187 79.2 34 14.4 236
Washington, DC 205 53.2 165 42.9 385
Total 3,866 67.8 1,552 27.2 5,698
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No. % No. % No.
.3 316 4.5 479 6.9 6,954
.3 27 7.4 37 10.1 366
.0 44 5.4 61 7.5 816
.2 86 5.3 131 8.0 1,633
.7 79 5.2 131 8.6 1,532
.2 80 3.1 119 4.6 2,607
.7 1 1.7 4 6.8 59
.1 2 9.1 2 9.1 22
.0 66 2.9 104 4.6 2,279
.7 105 6.3 149 9.0 1,659
.5 1 12.5 0 0.0 8
.6 126 4.7 196 7.3 2,671
.6 14 5.7 22 9.0 244
.2 123 24.3 56 11.1 506
.7 5 71.4 0 0.0 7
.6 14 60.9 3 13.0 23
.4 36 42.9 11 13.1 84
.3 45 28.7 24 15.3 157
.9 23 9.8 18 7.7 235
.0 2 50.0 1 25.0 4
.0 0 0.0 0 0.0 1
.5 29 13.1 19 8.6 221
.1 30 21.7 14 10.1 138
.0 0 0.0 0 0.0 1
.4 50 42.7 17 14.5 117
.1 11 52.4 4 19.0 21
.4 6 9.8 5 8.2 61
.0 445 5.9 540 7.2 7,521
Abbreviations: NHBS, National HIV Behavioral Surveillance; PWID, persons who inject drugs [footnotes only].
a PWID who reported oral, vaginal, or anal sex with at least 1 female partner and oral or anal sex with at least 1 male partner during the past 12 months.
b PWID with a valid negative NHBS HIV test result.
c Hispanics/Latinos can be of any race.
d PWID with a reactive rapid NHBS HIV test result confirmed by supplemental laboratory-based testing, or a positive result by laboratory-based testing without a rapid HIV test.
e PWID who did not have a valid HIV-positive or HIV-negative NHBS test result, including those who did not consent to the HIV test, had an indeterminate result, or reported a previo
test result.
Table 5. Sexual behavior during the 12 months preceding interview among males who inject drugs—National HIV Behavioral Surveillan
With female sex partners With male sex pa
Vaginal sex
Condomless 
vaginal sex Anal sex
Condomless 
anal sex Oral or anal sex Anal sex
No. % No. % No. % No. % No. % No. %
HIV-negativeb 5,624 80.9 4,866 70.0 2,232 32.1 1,735 24.9 632 9.1 437 6
Age at interview (yr)
18–24 325 88.8 291 79.5 136 37.2 98 26.8 53 14.5 34 9
25–29 719 88.1 657 80.5 344 42.2 264 32.4 86 10.5 57 7
30–39 1,421 87.0 1,269 77.7 637 39.0 519 31.8 171 10.5 118 7
40–49 1,230 80.3 1,066 69.6 523 34.1 414 27.0 167 10.9 118 7
≥50 1,929 74.0 1,583 60.7 592 22.7 440 16.9 155 5.9 110 4
Race/ethnicity
American Indian/Alaska Native 40 67.8 33 55.9 14 23.7 11 18.6 4 6.8 1 1
Asian 17 77.3 13 59.1 4 18.2 1 4.5 3 13.6 2 9
Black/African American 1,845 81.0 1,531 67.2 574 25.2 443 19.4 131 5.7 92 4
Hispanic/Latinoc 1,333 80.3 1,131 68.2 665 40.1 509 30.7 191 11.5 144 8
Native Hawaiian/Other Pacific Islander 7 87.5 6 75.0 2 25.0 1 12.5 1 12.5 1 12
White 2,181 81.7 1,975 73.9 892 33.4 703 26.3 270 10.1 175 6
Multiple races 189 77.5 167 68.4 74 30.3 60 24.6 30 12.3 21 8
HIV-positived 281 55.5 167 33.0 119 23.5 63 12.5 175 34.6 153 30
Age at interview (yr)
18–24 0 0.0 0 0.0 0 0.0 0 0.0 6 85.7 6 85
25–29 8 34.8 5 21.7 1 4.3 0 0.0 16 69.6 16 69
30–39 42 50.0 32 38.1 24 28.6 13 15.5 43 51.2 39 46
40–49 88 56.1 57 36.3 43 27.4 24 15.3 66 42.0 57 36
≥50 143 60.9 73 31.1 51 21.7 26 11.1 44 18.7 35 14
Race/ethnicity
American Indian/Alaska Native 2 50.0 2 50.0 0 0.0 0 0.0 3 75.0 2 50
Asian 1 100.0 1 100.0 0 0.0 0 0.0 0 0.0 0 0
Black/African American 133 60.2 76 34.4 47 21.3 29 13.1 50 22.6 43 19
Hispanic/Latinoc 82 59.4 47 34.1 48 34.8 20 14.5 41 29.7 36 26
Native Hawaiian/Other Pacific Islander 1 100.0 1 100.0 0 0.0 0 0.0 0 0.0 0 0
White 51 43.6 33 28.2 22 18.8 14 12.0 66 56.4 59 50
Multiple races 8 38.1 6 28.6 2 9.5 0 0.0 14 66.7 12 57
No valid NHBS HIV test resulte 42 68.9 36 59.0 16 26.2 12 19.7 12 19.7 10 16
Total 5,947 79.1 5,069 67.4 2,367 31.5 1,810 24.1 819 10.9 600 8
Abbreviations: NHBS, National HIV Behavioral Surveillance; PWID, persons who inject drugs [footnotes only].
a PWID who reported oral, vaginal, or anal sex with at least 1 female main partner and at least 1 female casual partner during the 12 months preceding interview.
b PWID with a valid negative NHBS HIV test result.
c Hispanics/Latinos can be of any race.
d PWID with a reactive rapid NHBS HIV test result confirmed by supplemental laboratory-based testing, or a positive result by laboratory-based testing without a rapid HIV test.
e PWID who did not have a valid HIV-positive or HIV-negative NHBS test result, including those who did not consent to the HIV test, had an indeterminate result, or reported a previous 
HIV-positive test result but had an HIV-negative NHBS HIV test result. 
Table 6. Sexual behavior with female sex partners during the 12 months preceding interview among males who inject drugs, by partner 
type—National HIV Behavioral Surveillance, 20 U.S. cities, 2015 
Main female partner Casual female partner Main and casual 
female partners—
sex of any typea
Total 
malesVaginal or anal sex
Condomless 
vaginal or anal sex Vaginal or anal sex
Condomless 
vaginal or anal sex
No. % No. % No. % No. % No. %  No.
HIV-negativeb 3,855 55.4 3,479 50.0 3,581 51.5 2,709 39.0 1,869 26.9 6,954
Age at interview (yr)
18–24 241 65.8 222 60.7 240 65.6 184 50.3 161 44.0 366
25–29 532 65.2 500 61.3 517 63.4 412 50.5 332 40.7 816
30–39 1,024 62.7 946 57.9 899 55.1 680 41.6 510 31.2 1,633
40–49 797 52.0 735 48.0 784 51.2 603 39.4 367 24.0 1,532
≥50 1,261 48.4 1,076 41.3 1,141 43.8 830 31.8 499 19.1 2,607
Race/ethnicity
American Indian/Alaska Native 29 49.2 24 40.7 22 37.3 16 27.1 12 20.3 59
Asian 9 40.9 7 31.8 12 54.5 10 45.5 5 22.7 22
Black/African American 1,307 57.3 1,122 49.2 1,077 47.3 774 34.0 563 24.7 2,279
Hispanic/Latinoc 865 52.1 763 46.0 874 52.7 661 39.8 414 25.0 1,659
Native Hawaiian/Other Pacific Islander 4 50.0 3 37.5 5 62.5 4 50.0 2 25.0 8
White 1,493 55.9 1,425 53.4 1,463 54.8 1,151 43.1 796 29.8 2,671
Multiple races 140 57.4 128 52.5 122 50.0 89 36.5 75 30.7 244
HIV-positived 166 32.8 99 19.6 182 36.0 108 21.3 70 13.8 506
Age at interview (yr)
18–24 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 7
25–29 5 21.7 3 13.0 5 21.7 3 13.0 2 8.7 23
30–39 19 22.6 14 16.7 28 33.3 21 25.0 5 6.0 84
40–49 57 36.3 39 24.8 58 36.9 37 23.6 27 17.2 157
≥50 85 36.2 43 18.3 91 38.7 47 20.0 36 15.3 235
Race/ethnicity
American Indian/Alaska Native 1 25.0 1 25.0 1 25.0 1 25.0 0 0.0 4
Asian 0 0.0 0 0.0 1 100.0 1 100.0 0 0.0 1
Black/African American 89 40.3 51 23.1 81 36.7 50 22.6 39 17.6 221
Hispanic/Latinoc 37 26.8 22 15.9 58 42.0 31 22.5 13 9.4 138
Native Hawaiian/Other Pacific Islander 1 100.0 1 100.0 0 0.0 0 0.0 0 0.0 1
White 31 26.5 20 17.1 34 29.1 22 18.8 14 12.0 117
Multiple races 5 23.8 4 19.0 4 19.0 2 9.5 2 9.5 21
No valid NHBS HIV test resulte 30 49.2 25 41.0 20 32.8 15 24.6 9 14.8 61
Total 4,051 53.9 3,603 47.9 3,783 50.3 2,832 37.7 1,948 25.9 7,521
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Abbreviations: NHBS, National HIV Behavioral Surveillance; PWID, persons who inject drugs [footnotes only].
a PWID with a valid negative NHBS HIV test result.
b Hispanics/Latinos can be of any race.
c PWID with a reactive rapid NHBS HIV test result confirmed by supplemental laboratory-based testing, or a positive result by laboratory-based testing without a rapid HIV test.
d PWID who did not have a valid HIV-positive or HIV-negative NHBS test result, including those who did not consent to the HIV test, had an indeterminate result, or reported a previous 
HIV-positive test result but had an HIV-negative NHBS HIV test result. 
Table 7. Sexual behavior with male sex partners during the 12 months preceding interview among females who inject drugs—National 
HIV Behavioral Surveillance, 20 U.S. cities, 2015 
Vaginal sex
Condomless 
vaginal sex Anal sex Condomless anal sex
Total 
females
No. % No. % No. % No. % No.
HIV-negativea 2,240 83.4 2,029 75.6 829 30.9 707 26.3 2,685
Age at interview (yr)
18–24 194 93.3 187 89.9 83 39.9 68 32.7 208
25–29 308 93.6 292 88.8 136 41.3 110 33.4 329
30–39 619 91.6 569 84.2 273 40.4 243 35.9 676
40–49 526 85.3 481 78.0 198 32.1 166 26.9 617
≥50 593 69.4 500 58.5 139 16.3 120 14.0 855
Race/ethnicity
American Indian/Alaska Native 28 73.7 26 68.4 12 31.6 11 28.9 38
Asian 3 60.0 3 60.0 3 60.0 3 60.0 5
Black/African American 636 75.6 551 65.5 199 23.7 169 20.1 841
Hispanic/Latinob 420 84.3 388 77.9 173 34.7 146 29.3 498
Native Hawaiian/Other Pacific Islander 5 71.4 5 71.4 2 28.6 2 28.6 7
White 1,026 88.7 942 81.4 397 34.3 337 29.1 1,157
Multiple races 119 88.8 111 82.8 41 30.6 37 27.6 134
HIV-positivec 151 74.4 95 46.8 54 26.6 31 15.3 203
Age at interview (yr)
18–24 1 100.0 1 100.0 0 0.0 0 0.0 1
25–29 8 88.9 4 44.4 3 33.3 2 22.2 9
30–39 22 91.7 16 66.7 11 45.8 7 29.2 24
40–49 66 78.6 44 52.4 30 35.7 18 21.4 84
≥50 54 63.5 30 35.3 10 11.8 4 4.7 85
Race/ethnicity
American Indian/Alaska Native 2 100.0 1 50.0 0 0.0 0 0.0 2
Asian 0 — 0 — 0 — 0 — 0
Black/African American 83 71.6 52 44.8 26 22.4 17 14.7 116
Hispanic/Latinob 27 71.1 17 44.7 12 31.6 6 15.8 38
Native Hawaiian/Other Pacific Islander 0 — 0 — 0 — 0 — 0
White 33 82.5 23 57.5 13 32.5 6 15.0 40
Multiple races 5 83.3 2 33.3 3 50.0 2 33.3 6
No valid NHBS HIV test resultd 19 86.4 15 68.2 2 9.1 2 9.1 22
Total 2,410 82.8 2,139 73.5 885 30.4 740 25.4 2,910
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Abbreviations: NHBS, National HIV Behavioral Surveillance; PWID, persons who inject drugs [footnotes only].
a PWID who reported oral, vaginal, or anal sex with at least 1 male main partner and at least 1 male casual partner during the 12 months preceding interview.
b PWID with a valid negative NHBS HIV test result.
c Hispanics/Latinos can be of any race.
d PWID with a reactive rapid NHBS HIV test result confirmed by supplemental laboratory-based testing, or a positive result by laboratory-based testing without a rapid HIV test.
e PWID who did not have a valid HIV-positive or HIV-negative NHBS test result, including those who did not consent to the HIV test, had an indeterminate result, or reported a previous 
HIV-positive test result but had an HIV-negative NHBS HIV test result.
Table 8. Sexual behavior with male sex partners during the 12 months preceding interview among females who inject drugs, by partner 
type—National HIV Behavioral Surveillance, 20 U.S. cities, 2015 
Main male partner Casual male partner Main and casual 
male partners—
sex of any typea
Total 
femalesVaginal or anal sex
Condomless 
vaginal or anal sex Vaginal or anal sex
Condomless 
vaginal or anal sex
No. % No. % No. % No. % No. % No.
HIV-negativeb 1,836 68.4 1,686 62.8 1,263 47.0 941 35.0 899 33.5 2,685
Age at interview (yr)
18–24 185 88.9 176 84.6 119 57.2 91 43.8 111 53.4 208
25–29 276 83.9 261 79.3 175 53.2 129 39.2 147 44.7 329
30–39 522 77.2 487 72.0 369 54.6 266 39.3 279 41.3 676
40–49 416 67.4 389 63.0 303 49.1 230 37.3 204 33.1 617
≥50 437 51.1 373 43.6 297 34.7 225 26.3 158 18.5 855
Race/ethnicity
American Indian/Alaska Native 24 63.2 22 57.9 20 52.6 16 42.1 16 42.1 38
Asian 3 60.0 3 60.0 1 20.0 0 0.0 1 20.0 5
Black/African American 479 57.0 422 50.2 355 42.2 273 32.5 217 25.8 841
Hispanic/Latinoc 333 66.9 311 62.4 253 50.8 196 39.4 171 34.3 498
Native Hawaiian/Other Pacific Islander 5 71.4 5 71.4 1 14.3 0 0.0 1 14.3 7
White 893 77.2 831 71.8 563 48.7 397 34.3 441 38.1 1,157
Multiple races 97 72.4 90 67.2 69 51.5 58 43.3 52 38.8 134
HIV-positived 103 50.7 67 33.0 84 41.4 48 23.6 42 20.7 203
Age at interview (yr)
18–24 0 0.0 0 0.0 1 100.0 1 100.0 0 0.0 1
25–29 5 55.6 2 22.2 4 44.4 2 22.2 1 11.1 9
30–39 19 79.2 14 58.3 10 41.7 6 25.0 8 33.3 24
40–49 47 56.0 31 36.9 42 50.0 26 31.0 27 32.1 84
≥50 32 37.6 20 23.5 27 31.8 13 15.3 6 7.1 85
Race/ethnicity
American Indian/Alaska Native 2 100.0 1 50.0 2 100.0 1 50.0 2 100.0 2
Asian 0 — 0 — 0 — 0 — 0 — 0
Black/African American 58 50.0 37 31.9 44 37.9 26 22.4 21 18.1 116
Hispanic/Latinoc 15 39.5 10 26.3 21 55.3 12 31.6 10 26.3 38
Native Hawaiian/Other Pacific Islander 0 — 0 — 0 — 0 — 0 — 0
White 24 60.0 17 42.5 14 35.0 8 20.0 7 17.5 40
Multiple races 4 66.7 2 33.3 2 33.3 1 16.7 2 33.3 6
No valid NHBS HIV test resulte 12 54.5 11 50.0 9 40.9 7 31.8 3 13.6 22
Total 1,951 67.0 1,764 60.6 1,356 46.6 996 34.2 944 32.4 2,910
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12 months Injected daily
Injected, past 
12 months
No. % No. % No. %
1,954 20.2 373 3.9 561 5.8 9,675
1,432 20.6 279 4.0 427 6.1 6,954
510 19.0 91 3.4 129 4.8 2,685
12 33.3 3 8.3 5 13.9 36
186 32.2 28 4.8 78 13.5 578
293 25.5 52 4.5 123 10.7 1,148
590 25.5 112 4.8 196 8.5 2,317
369 17.1 62 2.9 82 3.8 2,159
516 14.9 119 3.4 82 2.4 3,473
30 30.3 8 8.1 7 7.1 99
7 25.0 1 3.6 3 10.7 28
359 11.4 85 2.7 50 1.6 3,137
314 14.5 78 3.6 102 4.7 2,162
3 20.0 1 6.7 1 6.7 15
1,105 28.8 168 4.4 345 9.0 3,837
133 35.0 32 8.4 52 13.7 380
83 11.4 23 3.2 27 3.7 725
55 10.9 17 3.4 20 4.0 506
26 12.8 6 3.0 6 3.0 203
2 12.5 0 0.0 1 6.3 16
0 0.0 0 0.0 0 0.0 8
8 24.2 4 12.1 2 6.1 33
15 13.2 1 0.9 8 7.0 114
25 10.2 8 3.3 9 3.7 246
35 10.8 10 3.1 8 2.5 324
1 16.7 0 0.0 0 0.0 6
1 100.0 0 0.0 0 0.0 1
27 7.7 9 2.6 8 2.3 349
16 9.0 4 2.2 4 2.2 178
0 0.0 0 0.0 0 0.0 1
32 20.3 9 5.7 14 8.9 158
4 14.3 1 3.6 1 3.6 28
4 4.7 1 1.2 3 3.5 85
2,041 19.5 397 3.8 591 5.6 10,485
Abbreviations: NHBS, National HIV Behavioral Surveillance; PWID, persons who inject drugs [footnotes only].
Note. “Past 12 months” refers to the 12 months preceding interview.
a Heroin and cocaine being injected together.
b PWID with a valid negative NHBS HIV test result.
c Hispanics/Latinos can be of any race.
d PWID with a reactive rapid NHBS HIV test result confirmed by supplemental laboratory-based testing, or a positive result by laboratory-based testing without a rapid HIV test.
e PWID who did not have a valid HIV-positive or HIV-negative NHBS test result, including those who did not consent to the HIV test, had an indeterminate result, or reported a previo
test result.
Table 9. Injection drug use during the 12 months preceding interview, by selected drugs—National HIV Behavioral Surveillance, 20 U.S.
Heroin Speedballa Powder or crack cocaine Methamphetamine
Injected, past 
12 months Injected daily
Injected, past 
12 months Injected daily
Injected, past 
12 months Injected daily
Injected, past 
12 months Injected daily
No. % No. % No. % No. % No. % No. % No. % No. %
HIV-negativeb 8,733 90.3 7,168 74.1 4,504 46.6 1,897 19.6 3,819 39.5 1,276 13.2 2,656 27.5 905 9.4
Gender
Male 6,256 90.0 5,113 73.5 3,351 48.2 1,434 20.6 2,860 41.1 955 13.7 1,923 27.7 657 9.4
Female 2,451 91.3 2,037 75.9 1,136 42.3 457 17.0 939 35.0 312 11.6 717 26.7 240 8.9
Transgender 26 72.2 18 50.0 17 47.2 6 16.7 20 55.6 9 25.0 16 44.4 8 22.2
Age at interview (yr)
18–24 539 93.3 457 79.1 279 48.3 86 14.9 266 46.0 64 11.1 275 47.6 101 17.5
25–29 1,075 93.6 931 81.1 558 48.6 203 17.7 548 47.7 148 12.9 441 38.4 148 12.9
30–39 2,090 90.2 1,766 76.2 1,119 48.3 474 20.5 1,009 43.5 339 14.6 760 32.8 253 10.9
40–49 1,876 86.9 1,547 71.7 1,010 46.8 453 21.0 798 37.0 276 12.8 606 28.1 216 10.0
≥50 3,153 90.8 2,467 71.0 1,538 44.3 681 19.6 1,198 34.5 449 12.9 574 16.5 187 5.4
Race/ethnicity
American Indian/Alaska Native 86 86.9 64 64.6 42 42.4 17 17.2 44 44.4 13 13.1 50 50.5 21 21.2
Asian 24 85.7 18 64.3 11 39.3 2 7.1 8 28.6 1 3.6 12 42.9 7 25.0
Black/African American 2,913 92.9 2,327 74.2 1,564 49.9 799 25.5 1,161 37.0 514 16.4 298 9.5 107 3.4
Hispanic/Latinoc 1,888 87.3 1,605 74.2 1,026 47.5 580 26.8 702 32.5 294 13.6 494 22.8 178 8.2
Native Hawaiian/Other 
Pacific Islander 11 73.3 9 60.0 3 20.0 1 6.7 6 40.0 1 6.7 9 60.0 3 20.0
White 3,462 90.2 2,888 75.3 1,675 43.7 440 11.5 1,725 45.0 416 10.8 1,599 41.7 511 13.3
Multiple races 334 87.9 245 64.5 175 46.1 53 13.9 165 43.4 35 9.2 188 49.5 75 19.7
HIV-positived 549 75.7 431 59.4 376 51.9 214 29.5 287 39.6 132 18.2 209 28.8 89 12.3
Gender
Male 362 71.5 281 55.5 261 51.6 149 29.4 196 38.7 89 17.6 170 33.6 72 14.2
Female 178 87.7 144 70.9 106 52.2 61 30.0 83 40.9 39 19.2 31 15.3 12 5.9
Transgender 9 56.3 6 37.5 9 56.3 4 25.0 8 50.0 4 25.0 8 50.0 5 31.3
Age at interview (yr)
18–24 7 87.5 6 75.0 3 37.5 2 25.0 1 12.5 0 0.0 4 50.0 4 50.0
25–29 20 60.6 15 45.5 13 39.4 6 18.2 12 36.4 6 18.2 19 57.6 8 24.2
30–39 74 64.9 60 52.6 54 47.4 30 26.3 41 36.0 15 13.2 60 52.6 28 24.6
40–49 183 74.4 140 56.9 130 52.8 70 28.5 101 41.1 45 18.3 72 29.3 34 13.8
≥50 265 81.8 210 64.8 176 54.3 106 32.7 132 40.7 66 20.4 54 16.7 15 4.6
Race/ethnicity
American Indian/Alaska Native 2 33.3 1 16.7 1 16.7 1 16.7 0 0.0 0 0.0 6 100.0 4 66.7
Asian 1 100.0 1 100.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Black/African American 297 85.1 236 67.6 195 55.9 113 32.4 142 40.7 73 20.9 43 12.3 17 4.9
Hispanic/Latinoc 129 72.5 110 61.8 110 61.8 77 43.3 79 44.4 38 21.3 40 22.5 17 9.6
Native Hawaiian/Other 
Pacific Islander 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 100.0 1 100.0
White 101 63.9 72 45.6 57 36.1 16 10.1 56 35.4 18 11.4 94 59.5 39 24.7
Multiple races 16 57.1 9 32.1 10 35.7 6 21.4 8 28.6 2 7.1 22 78.6 11 39.3
No valid NHBS HIV test resulte 72 84.7 56 65.9 40 47.1 19 22.4 32 37.6 16 18.8 21 24.7 7 8.2
Total 9,354 89.2 7,655 73.0 4,920 46.9 2,130 20.3 4,138 39.5 1,424 13.6 2,886 27.5 1,001 9.5
Abbreviations: NHBS, National HIV Behavioral Surveillance; PWID, persons who inject drugs [footnotes only].
a A participant giving their needle to someone else to use after they had already used it for injection.
b Used a needle that had already been used by someone else for injection.
c Used a cooker (e.g., spoon, bottle cap) or cotton (to filter particles from drug solution) that had already been used by someone else or shared water for rinsing.
d Divided a drug solution by using a syringe that had already been used by someone else for injection.
e Used a needle that had already been used by someone else for injection, used a cooker or cotton that had already been used by someone else, shared water for rinsing, or divided a drug 
solution by using a syringe that had already been used by someone else for injection.
f PWID with a valid negative NHBS HIV test result.
g Hispanics/Latinos can be of any race.
h PWID with a reactive rapid NHBS HIV test result confirmed by supplemental laboratory-based testing, or a positive result by laboratory-based testing without a rapid HIV test.
i PWID who did not have a valid HIV-positive or HIV-negative NHBS test result, including those who did not consent to the HIV test, had an indeterminate result, or reported a previous HIV-
positive test result but had an HIV-negative NHBS HIV test result. 
Table 10. Sharing of injection equipment during the 12 months preceding interview among persons who inject drugs—National HIV Behavioral 
Surveillance, 20 U.S. cities, 2015 
Receptive sharing Distributive sharinga
Total No.
 Syringesb Injection equipmentc
Syringes to 
divide drugsd Anye Syringes
No. % No. % No. % No. % No. %
HIV-negativef 3,304 34.1 5,445 56.3 3,411 35.3 5,867 60.6 4,149 42.9 9,675
Gender
Male 2,288 32.9 3,872 55.7 2,368 34.1 4,169 60.0 2,928 42.1 6,954
Female 1,003 37.4 1,557 58.0 1,028 38.3 1,677 62.5 1,207 45.0 2,685
Transgender 13 36.1 16 44.4 15 41.7 21 58.3 14 38.9 36
Age at interview (yr)
18–24 303 52.4 405 70.1 274 47.4 440 76.1 358 61.9 578
25–29 574 50.0 783 68.2 523 45.6 837 72.9 647 56.4 1,148
30–39 971 41.9 1,478 63.8 959 41.4 1,588 68.5 1,225 52.9 2,317
40–49 709 32.8 1,190 55.1 745 34.5 1,285 59.5 907 42.0 2,159
≥50 747 21.5 1,589 45.8 910 26.2 1,717 49.4 1,012 29.1 3,473
Race/ethnicity
American Indian/Alaska Native 37 37.4 57 57.6 41 41.4 64 64.6 42 42.4 99
Asian 9 32.1 19 67.9 11 39.3 19 67.9 12 42.9 28
Black/African American 656 20.9 1,469 46.8 861 27.4 1,586 50.6 930 29.6 3,137
Hispanic/Latinog 765 35.4 1,230 56.9 842 38.9 1,320 61.1 1,017 47.0 2,162
Native Hawaiian/Other Pacific Islander 8 53.3 9 60.0 6 40.0 10 66.7 4 26.7 15
White 1,683 43.9 2,431 63.4 1,510 39.4 2,620 68.3 1,963 51.2 3,837
Multiple races 141 37.1 223 58.7 135 35.5 240 63.2 174 45.8 380
HIV-positiveh 182 25.1 352 48.6 242 33.4 382 52.7 153 21.1 725
Gender
Male 127 25.1 247 48.8 163 32.2 269 53.2 101 20.0 506
Female 50 24.6 96 47.3 72 35.5 104 51.2 47 23.2 203
Transgender 5 31.3 9 56.3 7 43.8 9 56.3 5 31.3 16
Age at interview (yr)
18–24 3 37.5 2 25.0 1 12.5 3 37.5 3 37.5 8
25–29 9 27.3 13 39.4 11 33.3 15 45.5 8 24.2 33
30–39 42 36.8 59 51.8 46 40.4 67 58.8 28 24.6 114
40–49 67 27.2 128 52.0 87 35.4 141 57.3 55 22.4 246
≥50 61 18.8 150 46.3 97 29.9 156 48.1 59 18.2 324
Race/ethnicity
American Indian/Alaska Native 2 33.3 3 50.0 1 16.7 4 66.7 1 16.7 6
Asian 1 100.0 1 100.0 1 100.0 1 100.0 1 100.0 1
Black/African American 65 18.6 166 47.6 105 30.1 176 50.4 65 18.6 349
Hispanic/Latinog 58 32.6 90 50.6 74 41.6 97 54.5 41 23.0 178
Native Hawaiian/Other Pacific Islander 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1
White 48 30.4 77 48.7 51 32.3 87 55.1 38 24.1 158
Multiple races 7 25.0 13 46.4 9 32.1 15 53.6 6 21.4 28
No valid NHBS HIV test resulti 22 25.9 42 49.4 29 34.1 44 51.8 30 35.3 85
Total 3,508 33.5 5,839 55.7 3,682 35.1 6,293 60.0 4,332 41.3 10,485
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Abbreviations: SSPs, syringe services programs; NHBS, National HIV Behavioral Surveillance; PWID, persons who inject drugs [footnotes only].
a Excludes condoms received from friends, relatives, or sex partners.
b Defined as either one-on-one conversations with an outreach worker, a counselor, or a prevention program worker about ways to prevent HIV, or participating in any organized sessions that 
involve a small group of people discussing ways to prevent HIV infections, excluding informal discussions with friends. Conversations that were part of obtaining an HIV test were excluded.
c PWID with a valid negative NHBS HIV test result. 
d Hispanics/Latinos can be of any race.
e PWID with a reactive rapid NHBS HIV test result confirmed by supplemental laboratory-based testing, or a positive result by laboratory-based testing without a rapid HIV test.
f PWID who did not have a valid HIV-positive or HIV-negative NHBS test result, including those who did not consent to the HIV test, had an indeterminate result, or reported a previous HIV-
positive test result but had an HIV-negative NHBS HIV test result. 
Table 11a. Receipt of HIV prevention materials and services during the 12 months preceding interview among persons who inject drugs—National HIV 





from SSPs Free condomsa
Individual- or group-
level interventionb
No. % No. % No. % No. % No. % Total No.
HIV-negativec 4,989 51.6 4,346 44.9 4,259 44.0 4,583 47.4 2,335 24.1 9,675
Gender
Male 3,566 51.3 3,122 44.9 3,043 43.8 3,292 47.3 1,615 23.2 6,954
Female 1,407 52.4 1,211 45.1 1,199 44.7 1,271 47.3 702 26.1 2,685
Transgender 16 44.4 13 36.1 17 47.2 20 55.6 18 50.0 36
Age at interview (yr)
18–24 284 49.1 325 56.2 249 43.1 271 46.9 102 17.6 578
25–29 609 53.0 653 56.9 543 47.3 531 46.3 248 21.6 1,148
30–39 1,269 54.8 1,210 52.2 1,126 48.6 1,141 49.2 536 23.1 2,317
40–49 1,106 51.2 874 40.5 941 43.6 1,032 47.8 542 25.1 2,159
≥50 1,721 49.6 1,284 37.0 1,400 40.3 1,608 46.3 907 26.1 3,473
Race/ethnicity
American Indian/Alaska Native 57 57.6 42 42.4 49 49.5 44 44.4 31 31.3 99
Asian 18 64.3 15 53.6 15 53.6 14 50.0 10 35.7 28
Black/African American 1,376 43.9 903 28.8 1,124 35.8 1,529 48.7 868 27.7 3,137
Hispanic/Latinod 1,188 54.9 1,028 47.5 997 46.1 1,088 50.3 541 25.0 2,162
Native Hawaiian/Other Pacific Islander 5 33.3 6 40.0 3 20.0 5 33.3 1 6.7 15
White 2,122 55.3 2,157 56.2 1,877 48.9 1,703 44.4 781 20.4 3,837
Multiple races 214 56.3 187 49.2 186 48.9 190 50.0 101 26.6 380
HIV-positivee 383 52.8 246 33.9 320 44.1 502 69.2 289 39.9 725
Gender
Male 279 55.1 181 35.8 231 45.7 352 69.6 188 37.2 506
Female 97 47.8 57 28.1 83 40.9 136 67.0 93 45.8 203
Transgender 7 43.8 8 50.0 6 37.5 14 87.5 8 50.0 16
Age at interview (yr)
18–24 4 50.0 3 37.5 3 37.5 7 87.5 4 50.0 8
25–29 19 57.6 13 39.4 16 48.5 27 81.8 11 33.3 33
30–39 56 49.1 48 42.1 46 40.4 80 70.2 46 40.4 114
40–49 128 52.0 91 37.0 112 45.5 173 70.3 93 37.8 246
≥50 176 54.3 91 28.1 143 44.1 215 66.4 135 41.7 324
Race/ethnicity
American Indian/Alaska Native 3 50.0 2 33.3 3 50.0 5 83.3 2 33.3 6
Asian 0 0.0 0 0.0 0 0.0 1 100.0 1 100.0 1
Black/African American 160 45.8 81 23.2 132 37.8 230 65.9 150 43.0 349
Hispanic/Latinod 110 61.8 77 43.3 87 48.9 118 66.3 65 36.5 178
Native Hawaiian/Other Pacific Islander 0 0.0 0 0.0 1 100.0 1 100.0 1 100.0 1
White 88 55.7 72 45.6 80 50.6 121 76.6 57 36.1 158
Multiple races 19 67.9 12 42.9 15 53.6 23 82.1 13 46.4 28
No valid NHBS HIV test resultf 43 50.6 31 36.5 44 51.8 60 70.6 33 38.8 85
Total 5,415 51.6 4,623 44.1 4,623 44.1 5,145 49.1 2,657 25.3 10,485
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Abbreviations: SSPs, syringe services programs; PWID, persons who inject drugs [footnotes only]; NHBS, National HIV Behavioral Surveillance [footnotes only].
a Excludes condoms received from friends, relatives, or sex partners.
b Defined as either one-on-one conversations with an outreach worker, a counselor, or a prevention program worker about ways to prevent HIV, or participating in any organized sessions that 
involve a small group of people discussing ways to prevent HIV infections, excluding informal discussions with friends. Conversations that were part of obtaining an HIV test were excluded.
c PWID with a valid negative NHBS HIV test result. 
d PWID with a reactive rapid NHBS HIV test result confirmed by supplemental laboratory-based testing, or a positive result by laboratory-based testing without a rapid HIV test.
Table 11b. Receipt of HIV prevention materials and services during the 12 months preceding interview among persons who inject drugs by area of 
residence—National HIV Behavioral Surveillance, 20 U.S. cities, 2015 
Syringes from SSPs Syringes from pharmacy
Injection equipment 
from SSPs Free condomsa
Individual- or group-
level interventionb
Total No.No. % No. % No. % No. % No. %
HIV-negativec
Atlanta, GA 177 45.6 169 43.6 137 35.3 205 52.8 104 26.8 388
Baltimore, MD 293 58.5 95 19.0 233 46.5 265 52.9 151 30.1 501
Boston, MA 330 67.5 394 80.6 297 60.7 265 54.2 215 44.0 489
Chicago, IL 324 61.4 408 77.3 306 58.0 232 43.9 130 24.6 528
Dallas, TX 8 1.6 199 40.4 3 0.6 122 24.7 71 14.4 493
Denver, CO 360 63.3 318 55.9 309 54.3 289 50.8 113 19.9 569
Detroit, MI 218 38.5 309 54.6 165 29.2 135 23.9 98 17.3 566
Houston, TX 14 3.0 264 55.8 5 1.1 181 38.3 116 24.5 473
Los Angeles, CA 351 68.8 221 43.3 319 62.5 271 53.1 139 27.3 510
Miami, FL 14 3.2 70 15.8 3 0.7 153 34.5 59 13.3 444
Nassau-Suffolk, NY 80 39.8 138 68.7 63 31.3 109 54.2 61 30.3 201
New Orleans, LA 189 32.8 178 30.8 137 23.7 271 47.0 85 14.7 577
New York City, NY 324 68.5 243 51.4 296 62.6 275 58.1 217 45.9 473
Newark, NJ 174 51.2 90 26.5 139 40.9 138 40.6 77 22.6 340
Philadelphia, PA 449 71.7 136 21.7 404 64.5 242 38.7 90 14.4 626
San Diego, CA 255 42.4 296 49.2 214 35.5 260 43.2 77 12.8 602
San Francisco, CA 407 89.6 215 47.4 373 82.2 300 66.1 99 21.8 454
San Juan, PR 295 61.5 299 62.3 213 44.4 311 64.8 131 27.3 480
Seattle, WA 389 77.0 228 45.1 362 71.7 261 51.7 119 23.6 505
Washington, DC 338 74.1 76 16.7 281 61.6 298 65.4 183 40.1 456
HIV-positived
Atlanta, GA 11 30.6 16 44.4 9 25.0 29 80.6 12 33.3 36
Baltimore, MD 51 68.9 6 8.1 46 62.2 46 62.2 33 44.6 74
Boston, MA 9 81.8 7 63.6 7 63.6 8 72.7 8 72.7 11
Chicago, IL 3 33.3 6 66.7 4 44.4 8 88.9 3 33.3 9
Dallas, TX 1 8.3 4 33.3 0 0.0 9 75.0 5 41.7 12
Denver, CO 14 58.3 14 58.3 13 54.2 21 87.5 16 66.7 24
Detroit, MI 7 46.7 8 53.3 4 26.7 7 46.7 5 33.3 15
Houston, TX 3 6.8 27 61.4 2 4.5 32 72.7 18 40.9 44
Los Angeles, CA 10 62.5 6 37.5 9 56.3 15 93.8 8 50.0 16
Miami, FL 0 0.0 8 10.5 0 0.0 43 56.6 26 34.2 76
Nassau-Suffolk, NY 4 50.0 5 62.5 3 37.5 5 62.5 4 50.0 8
New Orleans, LA 6 19.4 7 22.6 5 16.1 23 74.2 8 25.8 31
New York City, NY 35 70.0 21 42.0 32 64.0 32 64.0 24 48.0 50
Newark, NJ 16 37.2 12 27.9 11 25.6 25 58.1 15 34.9 43
Philadelphia, PA 29 90.6 6 18.8 26 81.3 17 53.1 10 31.3 32
San Diego, CA 10 50.0 5 25.0 7 35.0 13 65.0 10 50.0 20
San Francisco, CA 69 89.6 37 48.1 59 76.6 55 71.4 19 24.7 77
San Juan, PR 46 75.4 34 55.7 33 54.1 47 77.0 20 32.8 61
Seattle, WA 22 88.0 10 40.0 20 80.0 22 88.0 15 60.0 25
Washington, DC 37 60.7 7 11.5 30 49.2 45 73.8 30 49.2 61
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o. 18 -positive test result but had an HIV-negative NHBS HIV test result. 
 cities, 2015 
Diagnosis, ever
enital warts Genital herpes
. % No. % Total No.
3.2 382 3.9 9,675
2.7 220 3.2 6,954
4.4 161 6.0 2,685
2.8 1 2.8 36
1.2 24 4.2 578
2.3 36 3.1 1,148
3.0 90 3.9 2,317
4.4 102 4.7 2,159
3.1 130 3.7 3,473
8.1 7 7.1 99
0.0 1 3.6 28
2.5 113 3.6 3,137
2.4 96 4.4 2,162
6.7 1 6.7 15
3.9 140 3.6 3,837
5.0 22 5.8 380
8.7 64 8.8 725
9.7 44 8.7 506
5.4 18 8.9 203
18.8 2 12.5 16
0.0 0 0.0 8
18.2 2 6.1 33
7.0 7 6.1 114
6.9 25 10.2 246
9.9 30 9.3 324
16.7 0 0.0 6
0.0 0 0.0 1
9.5 29 8.3 349
3.4 12 6.7 178
0.0 0 0.0 1
12.7 20 12.7 158
10.7 3 10.7 28
1.2 5 5.9 85
3.5 451 4.3 10,485
Abbreviations: STI, sexually transmitted infection; NHBS, National HIV Behavioral Surveillance; PWID, persons who inject drugs [footnotes only].
aAny bacterial STI includes having received a diagnosis of gonorrhea, chlamydia, or syphilis during the 12 months preceding interview.
bPWID with a valid negative NHBS HIV test result. 
cHispanics/Latinos can be of any race.
dPWID with a reactive rapid NHBS HIV test result confirmed by supplemental laboratory-based testing, or a positive result by laboratory-based testing without a rapid HIV test.
ePWID who did not have a valid HIV-positive or HIV-negative NHBS test result, including those who did not consent to the HIV test, had an indeterminate result, or reported a previous HIV
Table 12. Diagnosis of sexually transmitted infections among persons who inject drugs—National HIV Behavioral Surveillance, 20 U.S.
Diagnosis during the 12 months preceding interview
Any bacterial STIa Chlamydia Gonorrhea Syphilis G
No. % No. % No. % No. % No
HIV-negativeb 411 4.2 225 2.3 180 1.9 111 1.1 306
Gender
Male 251 3.6 117 1.7 129 1.9 74 1.1 188
Female 158 5.9 108 4.0 51 1.9 35 1.3 117
Transgender 2 5.6 0 0.0 0 0.0 2 5.6 1
Age at interview (yr)
18–24 36 6.2 27 4.7 14 2.4 3 0.5 7
25–29 47 4.1 38 3.3 23 2.0 7 0.6 26
30–39 99 4.3 56 2.4 47 2.0 17 0.7 70
40–49 96 4.4 49 2.3 38 1.8 32 1.5 94
≥50 133 3.8 55 1.6 58 1.7 52 1.5 109
Race/ethnicity
American Indian/Alaska Native 2 2.0 1 1.0 1 1.0 1 1.0 8
Asian 1 3.6 0 0.0 1 3.6 0 0.0 0
Black/African American 166 5.3 78 2.5 84 2.7 48 1.5 77
Hispanic/Latinoc 74 3.4 37 1.7 27 1.2 28 1.3 52
Native Hawaiian/Other Pacific Islander 2 13.3 2 13.3 0 0.0 0 0.0 1
White 149 3.9 98 2.6 60 1.6 28 0.7 149
Multiple races 17 4.5 9 2.4 7 1.8 6 1.6 19
HIV-positived 80 11.0 31 4.3 38 5.2 52 7.2 63
Gender
Male 62 12.3 23 4.5 31 6.1 40 7.9 49
Female 15 7.4 8 3.9 7 3.4 9 4.4 11
Transgender 3 18.8 0 0.0 0 0.0 3 18.8 3
Age at interview (yr)
18–24 1 12.5 0 0.0 0 0.0 1 12.5 0
25–29 11 33.3 5 15.2 8 24.2 8 24.2 6
30–39 19 16.7 7 6.1 6 5.3 13 11.4 8
40–49 23 9.3 10 4.1 10 4.1 14 5.7 17
≥50 26 8.0 9 2.8 14 4.3 16 4.9 32
Race/ethnicity
American Indian/Alaska Native 0 0.0 0 0.0 0 0.0 0 0.0 1
Asian 0 0.0 0 0.0 0 0.0 0 0.0 0
Black/African American 29 8.3 10 2.9 13 3.7 22 6.3 33
Hispanic/Latinoc 22 12.4 8 4.5 12 6.7 13 7.3 6
Native Hawaiian/Other Pacific Islander 0 0.0 0 0.0 0 0.0 0 0.0 0
White 20 12.7 9 5.7 9 5.7 11 7.0 20
Multiple races 9 32.1 4 14.3 4 14.3 6 21.4 3
No valid NHBS HIV test resulte 6 7.1 0 0.0 3 3.5 4 4.7 1
Total 497 4.7 256 2.4 221 2.1 167 1.6 370
Abbreviations: NHBS, National HIV Behavioral Surveillance; PWID, persons who inject drugs [footnotes only].
a PWID with a valid negative NHBS HIV test result. 
b Hispanics/Latinos can be of any race.
c PWID with a reactive rapid NHBS HIV test result confirmed by supplemental laboratory-based testing, or a positive result by laboratory-based testing 
without a rapid HIV test.
d PWID who did not have a valid HIV-positive or HIV-negative NHBS test result, including those who did not consent to the HIV test, had an 
indeterminate result, or reported a previous HIV-positive test result but had an HIV-negative NHBS HIV test result. 
Table 13. Lifetime testing for hepatitis C virus and diagnosis of hepatitis C among persons who inject drugs—
National HIV Behavioral Surveillance, 20 U.S. cities, 2015 
Hepatitis C virus testing Hepatitis C diagnosis
No. % No. % Total No.
HIV-negativea 7,806 80.7 4,228 43.7 9,675
Gender
Male 5,590 80.4 3,057 44.0 6,954
Female 2,189 81.5 1,159 43.2 2,685
Transgender 27 75.0 12 33.3 36
Age at interview (yr)
18–24 372 64.4 115 19.9 578
25–29 877 76.4 358 31.2 1,148
30–39 1,881 81.2 927 40.0 2,317
40–49 1,736 80.4 935 43.3 2,159
≥50 2,940 84.7 1,893 54.5 3,473
Race/ethnicity
American Indian/Alaska Native 87 87.9 44 44.4 99
Asian 23 82.1 8 28.6 28
Black/African American 2,508 79.9 1,324 42.2 3,137
Hispanic/Latinob 1,686 78.0 960 44.4 2,162
Native Hawaiian/Other Pacific Islander 8 53.3 5 33.3 15
White 3,161 82.4 1,722 44.9 3,837
Multiple races 320 84.2 157 41.3 380
HIV-positivec 617 85.1 392 54.1 725
Gender
Male 427 84.4 278 54.9 506
Female 176 86.7 108 53.2 203
Transgender 14 87.5 6 37.5 16
Age at interview (yr)
18–24 3 37.5 1 12.5 8
25–29 27 81.8 14 42.4 33
30–39 97 85.1 55 48.2 114
40–49 212 86.2 119 48.4 246
≥50 278 85.8 203 62.7 324
Race/ethnicity
American Indian/Alaska Native 6 100.0 2 33.3 6
Asian 1 100.0 1 100.0 1
Black/African American 284 81.4 163 46.7 349
Hispanic/Latinob 150 84.3 106 59.6 178
Native Hawaiian/Other Pacific Islander 1 100.0 1 100.0 1
White 144 91.1 99 62.7 158
Multiple races 28 100.0 17 60.7 28
No valid NHBS HIV test resultd 72 84.7 45 52.9 85
Total 8,495 81.0 4,665 44.5 10,485
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Disclaimer: The use of trade names is for identification only and does not imply endorsement by the 
Department of Health and Human Services or the Centers for Disease Control and Prevention.
Abbreviations: NHBS, National HIV Behavioral Surveillance; PWID, persons who inject drugs 
[footnotes only].
Note. Denominator is the total number of PWID in the category; HIV-negative PWID: n = 9,675; HIV-positive 
PWID: n = 725; PWID without a valid NHBS HIV test result: n = 85. Responses are not mutually exclusive; 
percentages may not add to 100.
a PWID with a valid negative NHBS HIV test result.
b Defined as 5 or more drinks within about 2 hours (males) or 4 or more drinks within about 2 hours
   (females) during the 30 days preceding interview.
c Painkillers, such as Oxycontin, Vicodin, morphine, or Percocet. 
d Benzodiazepines, such as Valium, Ativan, or Xanax.
e PWID with a reactive rapid NHBS HIV test result confirmed by supplemental laboratory-based testing, or
a positive result by laboratory-based testing without a rapid HIV test.
f PWID who did not have a valid HIV-positive or HIV-negative NHBS test result, including those who did not
consent to the HIV test, had an indeterminate result, or reported a previous HIV-positive test result but 
had an HIV-negative NHBS HIV test result. 
Table 14. Noninjection drug use during the 12 months preceding interview and 
binge drinking during the 30 days preceding interview among 
persons who inject drugs—National HIV Behavioral Surveillance, 













Any noninjection drugs (excludes binge drinking) 7,311 75.6
HIV-positivee









Any noninjection drugs (excludes binge drinking) 486 67.0
No valid NHBS HIV test resultf









Any noninjection drugs (excludes binge drinking) 64 75.3
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sual female partner in exchange for sex, or giving or receiving 
a condom during his or her most recent sexual encounter.
us HIV-positive test result but had an HIV-negative NHBS HIV 




No. % Median (Q1–Q3) Total No.
5 1,667 17.2 18(7–32) 9,675
3 1,128 16.2 19(8–33) 6,954
7 532 19.8 14(6–28) 2,685
6 7 19.4 17.5(7–31.5) 36
4 81 14.0 4(2–6) 578
5 171 14.9 6(3–9) 1,148
2 342 14.8 12(6–17) 2,317
1 381 17.6 21(12–27) 2,159
5 692 19.9 36(28–42) 3,473
5 28 28.3 22(9–32) 99
6 5 17.9 11.5(4–19) 28
7 548 17.5 30(16–40) 3,137
8 351 16.2 18(7–28) 2,162
3 2 13.3 14(3–34) 15
3 655 17.1 11(5–21) 3,837
5 74 19.5 15(6–29) 380
2 170 23.4 24(15–35) 725
7 119 23.5 26(15–37) 506
9 46 22.7 22(14–31) 203
5 5 31.3 19.5(4.5–24) 16
0 2 25.0 3.5(2–6) 8
4 8 24.2 6(5–10) 33
9 27 23.7 14(7–20) 114
1 54 22.0 21.5(13–28) 246
5 79 24.4 36(29–41) 324
7 3 50.0 20(12–34) 6
0 0 0.0 45(45–45) 1
1 81 23.2 30(18–39) 349
3 25 14.0 22(14–32) 178
0 1 100.0 21(21–21) 1
7 44 27.8 19.5(10–30) 158
7 14 50.0 18(7.5–28.5) 28
7 19 22.4 21(6–36) 85
1 1,856 17.7 18(8–32) 10,485
Abbreviations: Q, quartile; PrEP, preexposure prophylaxis; NHBS, National HIV Behavioral Surveillance; SSP, syringe services program [footnotes only]; PWID, persons who inject d
a Number of heterosexual partners reported by participants during the 12 months before interview. 
b For females, “exchange sex” refers to receiving money or drugs from a casual male partner in exchange for sex. For males, “exchange sex” refers to giving money or drugs to a ca
money or drugs from a casual male partner in exchange for sex.
c “HIV-discordant partner” refers to a partner of different or unknown HIV status. “Condomless sex” refers to whether the participant reported engaging in vaginal or anal sex without 
d Ever heard of people who do not have HIV taking PrEP, the antiretroviral medicine taken every day for months or years to reduce the risk of getting HIV.
e Took PrEP at any point during the 12 months before interview to reduce the risk of getting HIV (not including time when taking antiretroviral medicine for only a few days at a time).
f Participated in drug treatment program during the 12 months before interview.
g Syringes were disposed of by putting them in a medical waste container and/or by exchanging them at an SSP, and no unknown or unsafe disposal method was indicated.
h PWID with a valid negative NHBS HIV test result. 
i Sexual behavior data not available for transgender PWID.
j Hispanics/Latinos can be of any race.
k PWID with a reactive rapid NHBS HIV test result confirmed by supplemental laboratory-based testing, or a positive result by laboratory-based testing without a rapid HIV test.
l PWID who did not have a valid HIV-positive or HIV-negative NHBS test result, including those who did not consent to the HIV test, had an indeterminate result, or reported a previo
test result. 
Table 15. Additional outcomes among persons who inject drugs—National HIV Behavioral Surveillance, 20 U.S. cities, 2015 







discordant partnerc Heard of PrEPd Took PrEPe
Received dru
treatmentf
Median (Q1–Q3) No. % No. % No. % No. % No. %
HIV-negative PWIDh 2(1–4) 2,472 25.6 2,984 30.8 937 9.7 33 0.3 4,303 44.
Gender
Male 2(1–3) 1,569 22.6 2,179 31.3 673 9.7 24 0.3 3,011 43.
Female 2(1–4) 903 33.6 805 30.0 253 9.4 8 0.3 1,281 47.
Transgenderi — — — — — 11 30.6 1 2.8 11 30.
Age at interview (yr)
18–24 2(1–5) 110 19.0 263 45.5 73 12.6 3 0.5 280 48.
25–29 2(1–5) 230 20.0 419 36.5 109 9.5 6 0.5 591 51.
30–39 2(1–4) 552 23.8 791 34.1 275 11.9 13 0.6 1,140 49.
40–49 2(1–4) 643 29.8 667 30.9 211 9.8 6 0.3 887 41.
≥50 1(0–3) 937 27.0 844 24.3 269 7.7 5 0.1 1,405 40.
Race/ethnicity
American Indian/Alaska Native 1(1–3) 25 25.3 28 28.3 14 14.1 0 0.0 48 48.
Asian 1(0–2) 5 17.9 6 21.4 2 7.1 0 0.0 15 53.
Black/African American 1(1–3) 990 31.6 837 26.7 241 7.7 7 0.2 1,276 40.
Hispanic/Latinoj 2(1–4) 561 25.9 684 31.6 207 9.6 9 0.4 925 42.
Native Hawaiian/Other Pacific Islander 1(1–3) 1 6.7 4 26.7 1 6.7 0 0.0 5 33.
White 2(1–4) 801 20.9 1,310 34.1 426 11.1 17 0.4 1,854 48.
Multiple races 2(1–4) 88 23.2 110 28.9 44 11.6 0 0.0 173 45.
HIV-positivek 1(0–2) 237 32.7 196 27.0 34 4.7 — — 284 39.
Gender
Male 1(0–2) 167 33.0 134 26.5 29 5.7 — — 191 37.
Female 1(1–3) 70 34.5 62 30.5 5 2.5 — — 87 42.
Transgenderi — — — — — 0 0.0 — — 6 37.
Age at interview (yr)
18–24 0(0–0) 4 50.0 3 37.5 0 0.0 — — 2 25.
25–29 1(0–2) 11 33.3 12 36.4 1 3.0 — — 12 36.
30–39 1(0–2) 41 36.0 34 29.8 9 7.9 — — 50 43.
40–49 1(0–3) 94 38.2 76 30.9 10 4.1 — — 79 32.
≥50 1(0–2) 87 26.9 71 21.9 14 4.3 — — 141 43.
Race/ethnicity
American Indian/Alaska Native 1.5(0–2) 1 16.7 1 16.7 0 0.0 — — 1 16.
Asian 1(1–1) 0 0.0 0 0.0 0 0.0 — — 0 0.
Black/African American 1(0–2) 106 30.4 90 25.8 17 4.9 — — 154 44.
Hispanic/Latinoj 1(0–3) 64 36.0 54 30.3 6 3.4 — — 61 34.
Native Hawaiian/Other Pacific Islander 1(1–1) 0 0.0 0 0.0 0 0.0 — — 0 0.
White 1(0–2) 51 32.3 44 27.8 11 7.0 — — 58 36.
Multiple races 0(0–1) 14 50.0 6 21.4 0 0.0 — — 10 35.
No valid NHBS HIV test resultl 1(1–2) 27 31.8 24 28.2 9 10.6 — — 38 44.
Total 1(1–3) 2,736 26.1 3,204 30.6 980 9.3 — — 4,625 44.
Abbreviations: PWID, persons who inject drugs [footnotes only]; NHBS, National HIV Behavioral Surveillance [footnotes only].
Note. Data include all PWID who reported having ever received an HIV-positive test result, including those who did not have a valid NHBS HIV test result (including those who did not 
consent to the HIV test). '”Past 6 months”' refers to the 6 months preceding interview.
a Hispanics/Latinos can be of any race. 
Table 16. Receipt of HIV care and treatment among self-reported HIV-positive persons who inject drugs—National HIV Behavioral Surveillance, 
20 U.S. cities, 2015 





Within 3 months 
after diagnosis During past 6 months
No. % No. % No. % No. %
Gender
Male 363 92.8 228 58.3 322 82.4 280 71.6 391
Female 140 90.3 87 56.1 131 84.5 106 68.4 155
Transgender 13 92.9 9 64.3 12 85.7 11 78.6 14
Age at interview (yr)
18–24 6 85.7 3 42.9 6 85.7 3 42.9 7
25–29 27 87.1 18 58.1 24 77.4 14 45.2 31
30–39 83 91.2 50 54.9 75 82.4 62 68.1 91
40–49 156 90.7 101 58.7 141 82.0 116 67.4 172
≥50 244 94.2 152 58.7 219 84.6 202 78.0 259
Race/ethnicity
American Indian/Alaska Native 6 100.0 1 16.7 6 100.0 4 66.7 6
Asian 1 100.0 1 100.0 1 100.0 1 100.0 1
Black/African American 244 93.5 149 57.1 221 84.7 197 75.5 261
Hispanic/Latinoa 118 89.4 65 49.2 103 78.0 89 67.4 132
Native Hawaiian/Other Pacific Islander 1 100.0 1 100.0 1 100.0 1 100.0 1
White 118 92.2 86 67.2 108 84.4 85 66.4 128
Multiple races 26 89.7 19 65.5 23 79.3 18 62.1 29
City
Atlanta, GA 29 93.5 13 41.9 28 90.3 20 64.5 31
Baltimore, MD 51 89.5 33 57.9 40 70.2 37 64.9 57
Boston, MA 13 100.0 9 69.2 13 100.0 9 69.2 13
Chicago, IL 8 88.9 4 44.4 8 88.9 4 44.4 9
Dallas, TX 6 100.0 5 83.3 6 100.0 5 83.3 6
Denver, CO 25 100.0 16 64.0 24 96.0 20 80.0 25
Detroit, MI 7 100.0 3 42.9 7 100.0 7 100.0 7
Houston, TX 34 91.9 22 59.5 31 83.8 28 75.7 37
Los Angeles, CA 10 90.9 6 54.5 10 90.9 9 81.8 11
Miami, FL 56 88.9 32 50.8 48 76.2 40 63.5 63
Nassau-Suffolk, NY 5 100.0 3 60.0 5 100.0 5 100.0 5
New Orleans, LA 19 90.5 13 61.9 15 71.4 13 61.9 21
New York City, NY 38 90.5 26 61.9 37 88.1 35 83.3 42
Newark, NJ 34 91.9 19 51.4 31 83.8 27 73.0 37
Philadelphia, PA 17 94.4 11 61.1 16 88.9 14 77.8 18
San Diego, CA 15 100.0 12 80.0 14 93.3 13 86.7 15
San Francisco, CA 61 95.3 40 62.5 55 85.9 39 60.9 64
San Juan, PR 25 71.4 11 31.4 18 51.4 17 48.6 35
Seattle, WA 23 100.0 16 69.6 22 95.7 20 87.0 23
Washington, DC 40 97.6 30 73.2 37 90.2 35 85.4 41
Total 516 92.1 324 57.9 465 83.0 397 70.9 560
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Participating Metropolitan Statistical Areas, 2015
Principal city Metropolitan statistical area division
Atlanta, Georgia Atlanta–Sandy Springs–Marietta, Georgia
Baltimore, Maryland Baltimore–Towson, Maryland 
Boston, Massachusetts Boston, Massachusetts–New Hampshire (Boston Division)
Chicago, Illinois Chicago, Illinois–Indiana–Wisconsin (Chicago Division) 
Dallas, Texas Dallas, Texas (Dallas Division) 
Denver, Colorado Denver–Aurora, Colorado
Detroit, Michigan Detroit, Michigan (Detroit Division)
Houston, Texas Houston–Baytown–Sugar Land, Texas
Los Angeles, California Los Angeles, California (Los Angeles Division) 
Miami, Florida Miami Florida (Miami Division) 
Nassau–Suffolk, New York New York, New York–New Jersey–Pennsylvania (Nassau Division)
New Orleans, Louisiana New Orleans–Metairie–Kenner, Louisiana 
New York, New York New York, New York–New Jersey–Pennsylvania (New York–White Plains–Wayne Division)
Newark, New Jersey New York, New York–New Jersey–Pennsylvania (Newark Division)
Philadelphia, Pennsylvania Philadelphia, Pennsylvania–New Jersey–Delaware–Maryland (Philadelphia Division)
San Diego, California San Diego–Carlsbad–San Marcos, California 
San Francisco, California San Francisco, California (San Francisco Division)
San Juan, Puerto Rico San Juan–Caguas–Guaynabo, Puerto Rico
Seattle, Washington Seattle, Washington (Seattle Division) 
Washington, DC Washington, District of Columbia (DC)–Virginia–Maryland–West Virginia (Washington Division)
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